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CHAPTER I
INTRODUCTION

Although contemporary medicine has celebrated
remarkable success in the treatment of symptoms and
etiology of microbial infections, the incidence of
progressively debilitating diseases such as
cardiovascular, neoplastic and neurological diseases has
increased unabated.

Second only to heart disease in

incidence, cancer is a disease characterized by germ line
mutations and progressive accumulation of somatic
mutations in genes regulating cellular growth and
differentiation.

Of over forty chemotherapeutic agents

approved for clinical use, no single, polypharmaceutical,
or multi-modality therapies have served as the
"mithridieum", or the magic bullet, for the eradication
of neoplastic disease in humans.
The oncologist has used chemotherapy as a front line
therapy, or in an adjuvant setting with radiation
therapy, hypothermia, and surgery in combating neoplastic
disease.

Curative regimens for the relatively rare adult

neoplastic transformations of testicular and
hematopoietic cells have been developed.

However, more

common forms of neoplasms such as colon, lung, and breast
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cancer have been refractory to chemotherapeutics which
target neoplastic DNA and intermediary metabolism.
Drug resistance can be defined as the ability of the
tumor cell to survive exposure to cytostatic and
cytocidal agents when administered at the maximum dose
tolerated by normal cells.

This phenomenon is an

interactive consequence of a number of host and tumor
cell factors.

Host factors include drug absorption,

distribution, metabolism, and excretion which can
decrease the bioavailability of agents to the tumor site.
Tumor cells possess a number of biochemical mechanisms of
drug resistance that decrease the intracellular
bioavailability of chemotherapeutic agents and facilitate
the repair of macromolecular damage inflicted by these
drugs.

The ultimate obstacle to therapeutic success is

the ability of the tumor cell to survive relatively
lethal concentrations of chemotherapeutic agents (O'Brien
and Cordon-Cardo, 1991).

Therefore, the identification

and selective inactivation of drug resistance mechanisms
could increase the therapeutic index of an antineoplastic agent.
A class of anti-neoplastic agents, the
chloroethylnitrosoureas (CENUs), has been employed in the
treatment of primary brain tumors, malignant melanoma,
Hodgkin's and non-Hodgkin's lymphomas, and multiple
myeloma, with encouraging results (Young, et al., 1971;
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Walker, 1973; Wilson, et al., 1976, Mortel, 1978).
However, the CENUs produce anti-tumor responses in fewer
than 20% of patients with non-hematological malignancies,
suggesting that the majority of human malignancies are
inherently resistant to the cytotoxic effects of these
agents (Carter, et al., 1976).

Evidence suggests this

limited effectiveness of CENUs is due to the presence of
the DNA repair protein, 0 6 -methylguanine DNA
methyltransferase (MGMT) in tumor cells (Myrnes et al.,
1984,; Chen, et al., 1992; Citron, et al.1991).

This

protein prevents the formation of the cytotoxic lesion
induced by CENU, the DNA interstrand cross-link
(Erickson, et al., 1980a; Yarosh, et al., 1983).
This dissertation describes pre-clinical studies
aimed at developing a novel chemotherapeutic regimen that
targets the extended depletion of MGMT in order to
increase the therapeutic effectiveness of one of the
CENUs, 1,3 bis(2-chloroethyl)-1-nitrosourea (BCNU).

This

regimen consists of the sequential administration of two
MGMT depleting agents, 0 6 -benzylguanine (BG) and
streptozotocin (STZ), prior to BCNU treatment.
Considerable evidence suggests that pretreatment of
resistant cells with MGMT depleting agents prior to CENU
exposure increases DNA cross-link formation and
cytotoxicity in resistant cells (Zlotogorski and
Erickson, 1983, 1984; Dolan et al., 1988; Dolan et al.,
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1990a,b).

The observation that the DNA interstrand

cross-link precursor 0 6 , N1 ethanoguanine is stable in
CENU treated DNA for greater than 8 hr following drug
removal suggests that the potential for cross-link
formation exists for extended periods (Brent, 1985b).
DNA interstrand cross-links produced by CENUs continue to
form 6-12 hr after drug removal in MGMT deficient cells
(Erickson et al., 1980a).

These data suggest that

extended depletion of MGMT throughout the time-course of
cross-link formation could maximize CENU cross-linking
and cytotoxicity.

If functional MGMT recovers during the

time-frame of cross-link formation in resistant cells,
then the enhancement of CENU cytotoxicity by MGMT
depleting agents would be sub-maximal.

The importance of

recovery of MGMT activity following MGMT depleting agents
in determining the potentiation of CENU cytotoxicity has
largely been neglected.

Therefore, experiments described

within this dissertation test the following hypothesis;
depletion of MGMT prior to, and for an extended period
following BCNU administration maximizes BCNU anti-tumor
activity in resistant cells.

In testing this hypothesis,

the combination of 0 6 -benzylguanine (BG) and
streptozotocin (STZ) was used in an effort to produce a
more extended depletion of MGMT, and a greater
enhancement of BCNU cytotoxicity than either STZ or BG
alone.

The enhancement of BCNU cytotoxicity was measured
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under conditions of extended depletion of MGMT for 24 hr
with the combination of BG+STZ, partial or complete
recovery of MGMT by 24 hr with BG or STZ as single
agents.

The combination of BG+STZ produced a more

prolonged depletion of MGMT and potentiated BCNU
cytotoxicity to a greater extent than either BG or STZ
alone.

However, the combination of BG+STZ+BCNU provided

no greater anti-tumor activity than BG+BCNU in vivo.

The

combination of BG+BCNU produced greater anti-tumor
activity than STZ+BCNU, and equivalent anti-tumor
activity to that of the three-drug combination. These
data demonstrate that extended depletion of MGMT
following BCNU treatment is required to maximize BCNU
cytotoxicity.

Additionally, the sequential use of BG,

STZ and BCNU probably results in a greater number of STZ
lesions which are responsible for the continued depletion
of MGMT and the greater enhancement of BCNU cytotoxicity
in vitro.
Collectively, these data suggest that clinical
regimens targeting the inactivation of MGMT and the
reversal of CENU resistance should be optimized such that
MGMT is depleted for extended periods following BCNU
administration.

Although BG can efficiently deplete MGMT

for prolonged periods in vitro and in vivo, it may not be
possible to achieve ample concentrations of BG to
inactivate MGMT in tumors with high levels of the protein
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for a prolonged period.

A possible means of reaching

this objective is by the combined use of the two MGMT
depleting agents, BG and STZ.

7

CHAPTER I I
REVIEW OF RELATED LITERATURE

Upon organization of the National Cancer Institute's
Chemotherapy Program in 1955, several transplantable
mouse tumors were selected for the evaluation of
potential anti-neoplastics because clinically useful
chemotherapeutic agents were effective against one or
more of these tumors (Gellhorn and Hirschberg, 1955).
Among these, systemic leukemia L1210 cells responds to
the greatest number of novel compounds of potential
clinical interest.
The 2-chloroethyl derivatives of the DNA methylating
agents 1-methyl-3-nitro-nitrosoguanidine (MNNG) and 1methyl-1-nitrosourea (MNU) showed greater anti-tumor
activity than the parent compounds in the L1210 leukemia
model (Skinner et al., 1960, Johnston et al., 1963).
Shortly thereafter, Skipper et al.

(1964) at the Southern

Research Institute demonstrated the curative ability of
BCNU against L1210 cells.

1-(2-chloroethyl)-3-

cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3(4-methylcyclohexyl)-l-nitrosourea (meCCNU) were
subsequently synthesized and showed similar anti-tumor
activity against Ll210 leukemia and Lewis lung carcinoma
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implants (Schabel, 1967, Mayo et al., 1972).

The anti-

tumor activities of the 1,3 di-substituted nitrosoureas
against a wide variety of rodent neoplasms has been
compiled by Schabel (1976).

This remarkable anti-tumor

activity produced by CENUs in mice led to the clinical
use of BCNU (Carmustine), CCNU (Lomustine), meCCNU
(Semustine), chlorozotocin, clomesone, and 1-(4-amino-2methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3nitrosourea (ACNU) .

Mechanism of Action of Chloroethylnitrosoureas

The macromolecular damage caused by the CENUs
includes alkylation of nucleic acids and carbamoylation
of lipids and proteins.

However, their antitumor

activity appears to be the consequence of DNA alkylation.
Among the plethora of base modifications, the di-adduct
DNA interstrand cross-link has been demonstrated as the
prominent cytotoxic lesion (Ewig and Kohn, 1977; Erickson
et al, 1980 a,b; Kohn et al, 1981).
At physiologic pH, CENU decompose into an alkylating
moiety (a chloroethyl diazo hydroxide which further
decomposed to yield a chloroethyl carbonium ion) and a
carbamoylating moiety (chloroethyl isocyanate)
(Montgomery, et al., 1967).

The formation of the DNA

interstrand cross-link occurs in a two-step reaction.
Cross-linking is thought to involve primary
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chloroethylation of a nucleophilic site on one strand of
DNA, with nucleophilic displacement of c1-, and subsequent
reaction with the opposite strand of DNA, resulting in a
covalent alkyl bridge between the two strands of DNA
(Kohn, 1977).

Initially, the chloroethyl carbonium ion

reacts with the 0 6 position of guanine within DNA and
produces 0 6 -chloroethylguanine (Tong et al., 1981).

This

monoadduct undergoes a slow intramolecular rearrangement
to form an 0 6 , N1 -ethanoguanine.

This cyclized

intermediate reacts with its complementary base cytosine
to form N1 -guanine, N3 -cytosine DNA interstrand cross-link
(Tong et al., 1982)

The initial alkylation and

cyclization requires a low activation energy and is
complete within minutes, whereas the later reaction
necessitates a higher activation energy and can take up
to 6-10 hr at 37°C for completion (Lown et al., 1978)
This time-course of cross-link formation appears to be
similar in isolated DNA (Kohn, 1977; Lown et al., 1978)
and DNA repair deficient cells (Erickson et al., 1980a)
The formation of DNA interstrand cross-links correlates
with inhibition of DNA replication and RNA transcription,
induction of G2 arrest and cytotoxicity (Gralla et al.,
1987; Pieper et al., 1989; Jiang et al., 1989).

The

importance of DNA cross-linking is further evidenced by
the sensitization of CENU resistant cells with drug
resistance modulators.

Depletion of the DNA repair
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protein MGMT by STZ or BG results in an increased number
of cross-links and an enhancement of CENU cytotoxicity
(Futscher et al, 1989; Mitchell et al, 1992)

These

studies will be described further below.
Alkylation of DNA is currently thought to be of
greater importance in mediating the anti-tumor activity
of CENUs than carbamoylation damage.

Although the rank

order of carbamoylating activity of a number of
nitrosoureas does not correlate with anti-tumor activity
(Heal et al, 1979; Wheeler et al, 1974), this activity
may have clinical importance.

The effects of

carbamoylation on cellular metabolism have been
extensively reviewed by Lea (1987) .
The primary clinical implications of macromolecular
carbamoylation damage resides in the CENU-mediated
inhibition of DNA repair and in the delayed
myelosuppression caused by CENU (Sarabin et al., 1984;
Ali-Osman, 1985). The chloroethyl isocyanate
carbamoylates the epsilon amino groups of lysine or
arginine residues in various cellular proteins (Holtham
and Schutz, 1949).

Carbamoylation alters protein

solubility and thereby limits protein function (Holtham
and Schutz, 1949).
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Carbamoylation and the Inhibition of DNA Repair

Using organic isocyanate derivatives of CENU, Kann et
al.

(1974) demonstrated a marked inhibition in the repair

of X-irradiation-induced DNA single strand breaks.
subsequent study by Fornace et al.

A

(1978) identified the

step most sensitive to carbamoylation damage as the religation of ultraviolet radiation-induced single strand
breaks.

The 2-chloroethyl isocyanate did not impair the

production of strand breaks and repair polymerase
activity, but inhibited DNA ligase activity.

These

observations suggest that the impairment of DNA ligase
activity is indicative of the inhibition of an excision
repair type mechanism which may contribute to the
cytotoxicity arising from CENU alkylation damage.
However, numerous studies suggest that carbamoylation
damage can inhibit DNA repair but can not substantially
contribute to the therapeutic effectiveness of CENU.
Clinically relevant doses of 2-chloroethyl isocyanate
(i.e. those approximated to be produced by lOOµM BCNU and
CCNU) do not inhibit repair of gamma-irradiation-induced
strand breaks and are non-toxic to L1210 or HeLa cells
(Hilton et al., 1978).

This contention is further

supported by the comparative effects on DNA repair and
cytotoxicity of two D-glucopyranosyl derivatives of MNU
with similar alkylating properties and divergent
carbamoylating activity.

The inhibition of DNA repair by
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the carbamoylating agent 3-beta-D-glucopyranosyl-1methyl-1-nitrosourea (GMNU) does not produce any greater
cytotoxicity than its non-carbamoylating congener STZ
(Heal, et al, 1979).

This inhibition of DNA repair could

have clinical relevance in radioresistance and may
explain the observed therapeutic synergism by the
combined administration of two CENUs (Kann et al, 1980;
Skipper, 1965).

The induction of DNA strand breaks

appears to be a primary mechanism of cell killing by Xirradiation.

Therefore, potent carbamoylating agents

like 1,3-bis (trans-4-hydorxycyclohexyl)-1-nitrosourea
(BCyNU) could be used to enhance the anti-tumor activity
of ionizing radiation (Kann et al., 1980).

Similarly,

the synergism between combined administration of two
CENUs could also be attributed to the inhibition of DNA
repair.

The direct interaction of CENUs and partially

purified MGMT results in the inactivation of the protein
(Brent, 1985a), presumably via carbamoylation.
Furthermore, excision repair has been implicated in BCNU
resistance (Swinnen, et al., 1991).

Therefore,

inactivation of one or both of these repair systems could
be the basis of the synergistic interaction of CENUs
observed when they were co-administered against rodent
tumors.
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Carbamoylation and CENU Induced Myelosuppression

Delayed myelosuppression is the dose limiting
toxicity of CENUs (Carter et al., 1972;

Schein et al.,

1975; Montgomery, 1976; Johnston, et al., 1986).

The

involvement of carbamoylation damage in the etiology of
myelosuppression is ambiguous.

The relative lack of bone

marrow toxicity of chlorozotocin (a CENU devoid of in
vitro carbamoylating activity and potent DNA crosslinking ability) suggests carbamoylation positively
relates to myelosuppression (Anderson et al., 1975;
Panasci et al., 1979).

However, other evidence suggest

that carbamoylation may not be responsible for
myelosuppression.

The relative in vitro carbamoylating

activity of several CENUs and methylnitrosoureas does not
correlate with bone marrow toxicity in mice (Panasci et
al., 1977; Brubaker et al., 1987).

Only a modest

relationship exists between the in vitro carbamoylation
activity and myelosuppression (Heal et al., 1979).

ACNU

and 1-(2-chloroethyl)-3-(1-deoxycyclo-inositol)-1nitrosourea, which has little in vitro carbamoylating
activity, produces comparable bone marrow toxicity to the
potent carbamoylating agent CCNU.

Additionally, another

potent carbamoylating agent 1-(2-chloroethyl)-3-(beta-Dglucopyranosyl)-l-nitrosourea (GANU) is not
myelosuppressive.

The significance of these data is

difficult to evaluate in light of the observations made
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by Gibson and Hickman (1982) that the in vitro
carbamoylating activity may not be predictive of in vivo
carbamoylation.

Experiments comparing BCNU,

chlorozotocin, GANU, and BCyNU-induced myelosuppression
suggest that myelosuppression may be associated more with
the qualitative types of carbamoylation damage than the
amount of damage (Ali-Osman et al., 1985).

The Relative Importance of Alkylation and Carbamoylation
Damage in CENU Cytotoxicity

A reductionist consideration of nitrosourea mechanism
of action in terms of alkylation versus carbamoylation
damage is "obviously simplistic"

(Lea, 1987).

The type

of carbamoylating moiety within a CENU determines its
lipid solubility and influences a number of
pharmacokinetic parameters (Hansch et al., 1972; Levin
and Kabra, 1974).

Once the drug localizes to the tumor,

alkylation damage could be of primary importance in
cytotoxicity (Lea, 1987) .

As previously stated, the rank

order of carbamoylating activity of a number nitrosoureas
does not correlate with the anti-tumor activity (Heal, et
al., 1979; Wheeler, et al., 1974).

Chlorozotocin, a CENU

with high cross-linking ability and minimal
carbamoylating activity, produces marginal anti-tumor
activity compared to congeners with both carbamoylating
and chloroethylating activity (Gibson and Hickman, 1982)
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Another potent carbamoylating agent, BCyNU devoid of
alkylating activity does not produce anti-tumor activity
(Kann et al., 1980).

The compound cis-2-0H-CCNU which

has lower carbamoylating activity than its parent
compound CCNU retains full anti-tumor activity (Wheeler,
1977). Furthermore, a convincing body of data correlating
CENU anti-tumor activity and DNA cross-linking in tumor
cell lines and xenografts suggests that the primary mode
of cell killing is due to alkylation of DNA (Kohn et al.,
1981; Thomas et al., 1978).

Mechanisms of CENU Resistance

Tumor cells become resistant by: 1) decreasing
cellular drug uptake and/or increasing drug efflux
(Waud., 1987; Vendrik et al., 1992); 2) increasing
intracellular detoxification of xenobiotics (Litterst, et
al., 1985; Waxman, 1990; Teicher and Frei, 1991); 3)
over-producing target proteins (Nunberg et al., 1978); 4)
decreasing levels of bioactivating enzymes (Dulhanty, et
al., 1989; Hoban et al., 1990); 5) increasing repair of
macromolecular damage (Barrows, et al., 1987; Batist, et
al., 1989; Bedford et al., 1988; Bodell, et al., 1988).
The plasma membrane protein P-glycoprotein facilitates
active efflux of a number of structurally unrelated
chemotherapeutic agents (Vendrik, et al., 1992).
Intracellular thiols such as glutathione and
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metallothionine act as nucleophilic sinks for a number of
DNA damaging agents (Teicher and Frei, 1991).

Anti-

metabolite drug resistance is imparted by the over
production of target proteins.

A well characterized

example of this type of mechanism is the amplification
and over- expression of the dihydrof olate reductase gene
in mediating methotrexate resistance (Nunberg et al.,
1978).

The decreased bioactivation of the pro-drug

mitomycin C appears to involve compromised microsomal
function (Hoban et al., 1990).

The mechanism of primary

importance to this dissertation is the increased cellular
capacity to repair macromolecular damage.

The mediation

of CENU resistance by the DNA repair protein MGMT and
modulation of such resistance will be extensively
discussed.

Furthermore, several secondary

mechanisms

implicated in CENU resistance will also be discussed
below.

MGMT and CENU Resistance

The CENU-induced DNA interstrand cross-link is formed
via an 0 6 -chloroethylguanine with subsequent cyclization
yielding 0 6 , N1 -ethanoguanine (Tong, et al., 1981, 1982)
This monoadduct interacts with the complementary base
cytosine and results in a guanine-cytosine DNA
interstrand cross-link.

Completion of cross-link

formation occurs in approximately 6-10 hr (Kohn, 1977;
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Erickson et al., 1980a; Brent, 1985).

This protracted

time course for cross-link formation allows the repair of
cross-link precursors by the 22 kd MGMT protein and
prevents the accumulation of the lethal lesions (Brent,
1985a) .
Tumor cell lines that prevent the formation of CENUinduced DNA interstrand cross-links are resistant to CENU
cytotoxicity (Erickson et al., 1980 a,b).

This

resistance phenotype correlates well with the ability of
a cell line to reactivate MNNG-damaged adenovirus.

The

phenotypic proficiency or deficiency in the reactivation
of damaged adenovirus is referred to as MEthylation
Repair positive (MER+) or MEthylation Repair negative
(MER-), respectively (Day et al., 1980a).

The MER

phenotype (Day et al., 1980b) is also related to 0 6 methylguanine repair capability, and this ability or
inability is designated Methyl Excision positive (Mex+) or
Methyl Excision negative (Mex-), respectively (Salker and
Strauss, 1981).

These data suggest that CENU resistance,

cross-link formation, reactivation of MNNG-damaged
adenovirus, and 0 6 -methylguanine repair are closely
associated (Erickson, 1991) .
The purified E. coli 0 6 -alkylguanine-DNA
alkyltransferase prevents the formation of BCNU crosslinks in damaged M13mp9 DNA in vitro (Robbins et al.,
1983).

This bacterial counterpart of MGMT quenchs cross-
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link formation when incubated with the damaged template
immediately after drug removal.

However, increasing the

interval between BCNU treatment of DNA and protein
incubation by several hours allows cross-link formation
(Robbins et al., 1983).

These data suggest that the

alkyltransferase protein repairs cross-link precursors,
however, once the cross-links are formed, the protein is
no longer effective.

Experiments using a variety of CENU

damaged templates and the human alkyltransferase MGMT
further substantiate these observations (Brent, 1984,
1985a) .

Cells with high levels of MGMT activity are more

resistant to CENU cytotoxicity than cells with little or
no MGMT activity (Brent et al., 1985b, Yarosh et al.,
1985; Robbins et al., 1983).
The cross-link precursors 0 6 -chloroethylguanine and
06,

N1 -ethanoguanine appear to be substrates for MGMT

(Brent et al., 1985a; 1988; 1990).

Interaction with the

cyclized intermediate results in a covalent cross-linking
of the MGMT protein to DNA via the N-1 position of
guanine (Gonzaga et al., 1990).

Repair of the 0 6 -

chloroethyl monoadduct, or the formation of the DNA-MGMT
cross-link quenchs DNA interstrand cross-link formation
(Brent et al., 1983a; 1988; 1990; Gonzaga et al., 1990).
There appears to be no regeneration of the alkylated MGMT
molecule and recovery of functional protein could not be
distinguished from de nova synthesis (Yarosh et al.,
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1986) .

The repair of 0 6 -alkylguanine by MGMT is

stoichiometric; one MGMT molecule repairs one alkyl
lesion from the 0-6 position of guanine (Pegg et al.,
1983).

Studies exploiting this suicidal property of MGMT

to induce a temporary MER- phenotype to CENU resistant
cells will be elaborated below.
Experiments introducing various MGMT complementary
DNAs into Mer- cells demonstrated the direct
cytoprotective effect of MGMT.

Cytotoxicities of BCNU,

ACNU, and chlorozotocin are markedly reduced by the
transf ection of the MGMT or ada cDNAs into repair
deficient cells (Ling-Ling et al., 1992; Hayakawa et al.;
1992, Samson et al., 1986; Kataoka et al., 1986; Barrows
et al. 1987) .
Pegg et al.

(1983, 1990, 1993) have proposed the

following mechanism for the transfer of alkyl groups from
the 0-6 position of guanine to MGMT.

Based on

comparative cDNA sequence analysis and site-directed
mutagenesis studies, the active site in MGMT has been
assigned putatively to the -Pro-Cys-His-Arg-Val- motif
representing the amino acid residues 144-148 of the MGMT
protein (Ling-Ling et al., 1992).

Site directed mutation

of the cys-145 residue to valine renders the protein
inactive (Ling-Ling et al., 1992).

The Cys-145 residue

within peptide sequence appears to be the alkyl acceptor
site within MGMT (Olsson and Lindahl, 1980; Mehta et al.,
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1981; Pegg et al., 1983; Ling-Ling et al., 1992).
Mechanistically, the alkyl group transfer could be
facilitated by the generation of a thiolate anion from
the cysteine acceptor, and the adjacent arginine and
histidine residues aid in the formation and stabilization
of the anion.

This thiolate anion could attack the alkyl

group at the 0-6 position of guanine yielding the native
guanine and the alkylated protein.

This reaction does

not require any other proteins or cofactors, and has a pH
optimum of 7.8-8.5 (Pegg et al., 1983).

The alkyl group

transfer may be a bi-molecular displacement reaction
resembling the first half of the ping-pong enzyme
mechanism where a functional group is transferred from
the substrate to the active site of the enzyme, resulting
in a covalent linkage (Pegg, 1990).

The isolation of an

alkylcysteine residue from MGMT incubated with methylated
DNA or BG provides strong evidence for this mechanism
(Pegg et al., 1983, 1993).

However, the exact molecular

mechanism of this reaction remains to be deduced.

Site

directed mutagenesis studies indicate that the histidine
and valine residues in the active site are not essential
for repair of methylated DNA (Ling-Ling et al., 1992).
Experiments examining substrate specificity and rate
constants for these mutant MGMT proteins must be
performed to clarify their role in the catalytic transfer
(Pegg et al., 1993).
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Pharmacologic Depletion of MGMT and Reversal of CENU
Resistance

Reversal of CENU resistance by DNA methylating agents.

Methylating agent-induced 0 6 -methylguanine lesions in
DNA appears to be important in mutagenesis,
carcinogenesis, and cytotoxicity.

This lesion in DNA is

currently the most efficient substrate for MGMT with a
second order rate constant of 0.02 x 10 8 mo1- 1 min- 1 (Pegg
The 0 6 -

et al., 1984; Bhattacharyya et al., 1990).

methylguanine lesions in DNA produced by methylating
agents are repaired by MGMT and result in the
inactivation of the protein (Brent, 1986) .

Methylating

agents are collectively referred to as indirect MGMT
depleting agents because they must first react with DNA
in order to provide a substrate for MGMT.
The suicidal nature of MGMT-mediated repair of 0 6 methylguanine lesion has been exploited to enhance CENU
cytotoxicity in resistant cells in vitro.

Pre-treatment

of resistant cells with MNNG results in the inactivation
of MGMT, and thereby can potentially increase alkylating
agent cytotoxicity (Waldstein et al., 1982).

Pre-

treatment of the CENU resistant cell lines IMR-90 and HT29 with non-toxic doses of MNNG prior to CENU
administration produces increased CNU-induced DNA
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interstrand cross-links and cell killing (Zlotogorski and
Erickson, 1983).

Similarly, non-toxic doses of MNU, STZ

and methyl methane sulfonate can also increase CNU crosslink formation and cytotoxicity in HT-29 cells
(Zlotogorski and Erickson, 1984; Erickson et al., 1988).
In the same cell line, mitozolamide-induced cytotoxicity
and cross-link formation are enhanced by MNNG or STZ pretreatment (Gibson and Erickson, 1985; Gibson et al.,
1986).

Furthermore, a non-toxic dose of STZ (2.5

rnM)

inhibits MGMT activity and increases cross-link formation
and cytotoxicity in HT-29 cells (Futscher et al., 1989).
Serial administration of temozolamide or dacarbazine and
BCNU depletes MGMT and increases BCNU cytotoxicity in HT29 cells in vitro (Mitchell and Dolan, 1993).

However,

the administration of STZ, dacarbazine, or temozolamide
prior to BCNU produces negligible MGMT inactivation and
growth inhibition of colon carcinoma, medulloblastoma and
glioblastoma xenografts (Mitchell and Dolan, 1993;
Friedman et al., 1992).
The in vitro effectiveness of the methylating agents
in sensitizing CENU resistant cells prompted the phase
I/phase II clinical testing of the combination of STZ and
BCNU (Micetich et al., 1992; Panella, 1992; Willson,
1992)

The dose limiting toxicities of the combination

include thrombocytopenia, transient hypophosphatemia, and
proteinuria.

Additionally, the maximally tolerated dose
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of BCNU when combined with STZ is reduced by 50%
(Micetich, et al., 1992).

The intrinsic cytotoxic

potential of STZ and the lack of tumor selective
inactivation of MGMT may be responsible for the apparent
exacerbation of BCNU toxicity (Willson, 1992; Micetich,
et al., 1992).

Therefore, the clinical use of STZ in the

inactivation of MGMT and the reversal of BCNU resistance
might be limited.

Furthermore, the clinical use of

methylating agents as MGMT depleting agents could
increase the chance of secondary malignancies because
MGMT plays a pivotal role in the prevention of MNU and
MNNG induced mutagenesis and carcinogenesis (Dumenco et
al., 1993; Nakatsuru, et al., 1993).

Inactivation of MGMT and reversal of CENU resistance
by guanine analogs.

The guanine analogs which deplete MGMT include 0 6 methylguanine (MG) , 0 6 -benzylguanine (BG) , and a series of
alkyl, halogenated and nucleoside derivatives of BG
(Karran, 1985; Dolan et al., 1990b; Moschel et al.,
1992) .

The free base MG was initially thought to deplete

MGMT by serving as a misincorperated substrate within tRNA (Karran, 1985).

However, the incorporation of the

free base into nucleic acids is not necessary to deplete
MGMT activity (Dolan et al., 1985).

MG can produce

substantial, albeit, incomplete depletion of MGMT
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activity in HeLa cells by serving as a substrate for MGMT
(Dolan et al., 1985).

Incubation of 0 6 -methyl-[ 3 H]-

guanine with HeLa cell extract containing MGMT results in
stoichiometric repair suggesting that MG directly
interacted with MGMT (Dolan et al., 1985).

The rate of

repair of MG is 10 7 times slower than when contained
within double stranded DNA suggesting MG is a poor
substrate for MGMT (Yarosh, 1986).

Pre-treatment of

several resistant cell lines with millimolar
concentrations of MG for periods of 4 hr or longer
results in 80% depletion of MGMT and 1-2 log potentiation
of CNU, CCNU, meCCNU, HeCNU, and BCNU cytotoxicities in
vitro (Dolan et al., 1986; Yarosh et al., 1986, Thielmann
et al., 1987, Dempke et al., 1987).

Additionally, MG can

also deplete MGMT activity, increase BCNU and clomesone
induced cytotoxicity and enhance DNA interstrand crosslinking in HT-29 cells (Dolan et al., 1988).

In contrast

to its in vitro effectiveness, MG only partially
inactivates MGMT and fails to inhibit the growth of HT-29
xenografts implanted in nude mice when combined with BCNU
(Dolan et al, 1989).

This incomplete MGMT inactivation

in tumor xenograf ts and rodent tissues requires extremely
large doses of MG (Pegg, 1990).

The low affinity of MG

for MGMT, lack of in vivo enhancement of CENU
cytotoxicity, and the limited solubility of MG are
considerable difficulties for the clinical use of MG.
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Based on the premise that a benzyl group could more
readily participate in a bimolecular displacement
reaction than a methyl group, Dolan et al.

(1990 a,b)

demonstrated that the free base 0 6 -benzylguanine (BG) was
a potent, non-toxic, irreversible inactivator of MGMT.
As little as 2 µM BG can completely ablate MGMT activity
within 5 min in HT-29 extracts (Dolan et al., 1990 b).
Incubation of [ 3 H]-0 6 -benzylguanine with extracts
containing MGMT results in the liberation of
stoichiometric amounts of [ 3 H]-guanine.

Furthermore, the

inactivation of MGMT leads to the formation of

s-

benzylcysteine within the protein (Pegg et al., 1993).
These data suggest that BG directly interacts with MGMT,
serves as a substrate for alkyl transfer, and yields a
native guanine and the benzylated protein.

The second

order rate constant for this reaction is 600 M- 1 s- 1 (Pegg
et al., 1993).

Evidence further suggests that

benzylation of MGMT induces a conformational change in
the protein which may stimulate rapid proteolytic
digestion of the inactive protein (Pegg, et al., 1991)
Site-directed mutagenesis studies suggest that the cys145 residue is the alkyl acceptor site and pro-140 is an
integral component of the BG hydrophobic binding site
within MGMT.

This proline 140 residue is replaced by an

alanine residue in the bacterial alkyltransferase ada and
may be partially responsible for the differential
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sensitivity of the two proteins to BG (Crone and Pegg,
1993).

In addition, the sequences in the divergent 28

amino acid tail within MGMT appear to be involved in the
BG binding site since the deletion of this tail reduces
BG mediated inhibition of MGMT by 5 fold (Morgan et al.,
1993) .
The inactivation of MGMT and reversal of CENU
resistance by BG has been demonstrated in numerous tumor
cell lines and xenografts.

Treatment of HT-29 cells with

micromolar doses of BG prior to clomesone, BCNU, CCNU, or
chlorozotocin administration results in the potentiation
of CENU cytotoxicity (Dolan et al., 1991).

Pretreatment

with BG also results in the induction of BCNU interstrand
cross-links, reduction in colony formation, and
significant inhibition of HT-29 and SF767 xenograft
growth (Dolan et al, 1990a; Mitchell et al., 1992).

The

enhancement of ACNU cytotoxicity or the dose modification
factor ( IC 50 ACNU alone/IC 50 BG+ACNU) is related to the
functional MGMT content in a cell line or xenograft (Chen
et al., 1993 a,b).

The rank order of enhancement of BCNU

cytotoxicity in several cell lines by BG appears to be a
function of MGMT activity (Dolan et al., 1991; Chen et
al., 1993 a,b).

This phenomenon has been corroborated in

vivo by Dolan et al.

(1993 b) by testing the anti-tumor

activity of the combination of BG+BCNU against four colon
carcinoma xenografts with high, intermediate, and low
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levels of MGMT activity.

The effectiveness of this

combination in vivo is further evidenced by the induction
of partial and complete regression of medulloblastoma and
glioblastoma tumors implanted subcutaneously, and
intracranially (Friedman et al., 1992; Felker et al,
1993).

The modulation of BCNU resistance in vivo in a

colon cancer xenograft (Vaco 6) has subsequently been
accomplished by repeated administrations of BG (Gerson et
al., 1993).

In this study, tumor bearing animals were

administered BG pre- and 2 hr post-BCNU treatment.

The

post-BCNU administration of BG may have inactivated
nascent MGMT molecules which could have maximized the
formation of DNA interstrand cross-links (Gerson et al.,
1993).

The host toxicity of the combined use of a CENU

and BG necessitates at least a 50% reduction in the dose
of the CENU in many of these animal experiments. Data
from histopathological examination of several rat tissues
from BCNU and the combination of BG and BCNU treated
rats, suggest that the dose-limiting determinants are due
to gastrointestinal, splenic, and hematopoietic
dysfunction (Dolan et al., 1993a).
CENU resistance modulation has predominately operated
on the premise that MGMT should be initially depleted,
prior to CENU exposure, in order to sensitize resistant
cells to CENU cytotoxicity.

However, CENU-induced cross-

links continue to form for an extended period of 6-12 hr
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after CENU removal (Erickson et al., 1980a).

It is

possible that any newly synthesized MGMT following a
resistance modulator could conceivably react with a
cross-link precursor and decrease the formation the
lethal DNA interstrand cross-link.

Therefore, in order

to maximize cross-link formation and cytotoxicity, MGMT
should be inactivated throughout the time course of
cross-link formation.

Experiments described within this

dissertation address this hypothesis by determining
whether extended depletion of MGMT after BG, STZ, and the
combination of BG and STZ is indeed required to maximize
BCNU cytotoxicity.

Role of Glutathione in CENU resistance

The majority of data strongly indicate that DNA
interstrand cross-links are the predominant cytotoxic
lesions and that MGMT plays a pivotal role in CENU
resistance by preventing cross-link formation.

However,

several other mechanisms of CENU resistance have also
been implicated.

In four medulloblastoma cell lines, a

relationship between cellular content of MGMT activity
and BCNU cytotoxicity was not demonstrated (Silber, et
al., 1992).

Additionally, cells expressing MGMT could

not be sensitized to BCNU cytotoxic effects by BG
pretreatment (Silber, et al., 1992).

In a subsequent

study, a panel of eight human brain tumors with low to
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high levels of MGMT activity were not appreciably
sensitized to BCNU cytotoxicity by BG.

The authors

suggested that MGMT was not a primary determinant in
predicting BCNU sensitivity in their cell lines and that
in vivo BCNU resistance in brain tumors may be
independent of MGMT content (Bobola et al., 1993)

These

data suggest that other mechanisms of CENU resistance may
exist in MGMT expressing cell lines.

A secondary

mechanism of CENU resistance may involve the
intracellular detoxification of CENU by glutathione
(GSH) .
Glutathione is present in mammalian cells at
intracellular concentrations of 5-10 mM (Kosower and
Kosower, 1978).

This tripeptide (Glu-Cys-Gly) contains a

strong nucleophilic thiol group within the cysteine
residue that can act as a nucleophilic sink for numerous
electrophiles such as free radicals, reactive oxygen
species, and many other endogenous and exogenous
compounds (Chesseud, 1979; Meister and Anderson, 1983).
The xenobiotics which react with GSH include cisplatin
and the DNA alkylating agents melphalan, BCNU, and
nitrogen mustard (Moscow et al., 1989; Hantel., et al
1991; Evans et al., 1987).

Conjugation of these

electrophiles with GSH convert them to non-toxic
metabolites which are transported extracellularly and
degraded by proteases (Bakke, 1990).

The conjugation
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occurs both in enzymatic and non-enzymatic processes.
The enzymatic process is mediated by a class of
glutathione-S-transferases (GST) which may determine
substrate specificity.
Treatment of cells with BCNU pre-incubated with GSH
prior to cell exposure in vitro results in increased
clonogenicity, decreased DNA interstrand cross-linking,
and decreased the inhibition of DNA replication in a
human glioblastoma cell line (Ali-Osman et al., 1989
a,b).

Ali-Osman et al.

(1989a) suggested that the

conjugation of GSH with the cross-link precursor 0 6 chloroethylguanine in DNA may result in the formation of
1-(0 6 -deoxyguanosyl), 2-S-glutathionylethane.

The

formation of this conjugate may prevent the
intramolecular rearrangement and subsequent reaction with
the complementary base cytosine, and thereby quench
cross-link formation (Ali-Osman, 1989a) .

The Pi and Mu

isozymes of GST mediate the conjugation of BCNU with GSH
followed by subsequent denitrosation of BCNU.

The Pi

class of isozymes appears to be responsible for
detoxification of BCNU in human brain tumor cells (AliOsman et al., 1990), whereas the Mu isozymes mediate the
conjugation of GSH and BCNU in rat brain tumor cells
(Smith et al., 1989).

The significance of GSH in BCNU

resistance is unclear since many of the studies which
addressed the role of GSH and BCNU resistance did not
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assess the relative contribution of such resistance
conferred by MGMT.
Sensitization of the HT-29 cell line, a MER+ colon
carcinoma cell line, to BCNU cytotoxicity by depleting
GSH has been attempted by Hantel et al.

(1990).

This

cell line contains 14-15 fold greater GSH and GST
activity than its MER- counterpart BE.

Reduction in HT-29

GSH content by more than 80% with buthionine sulfoximine
(BSO)

(a competitive inhibitor of the rate limiting

enzyme in GSH biosynthesis, gamma-gultamyl synthase) does
not modify BCNU cytotoxicity.

HT-29 cells contain high

levels of MGMT activity, and without MGMT depletion, the
significance of GSH depletion in BCNU resistance in MER+
cells would be difficult to assess.

Because MGMT is

clearly an important mechanism of resistance in MER+
cells, any secondary consequence of GSH depletion would
have been masked by MGMT repair function.

In order to

partially resolve this issue, an experiment
simultaneously targeting MGMT and GSH depletion is
described in Appendix I.
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CHAPTER III
PROLONGED DEPLETION OF 0 6 -METHYLGUANINE DNA
METHYLTRANSFERASE ACTIVITY (MGMT) FOLLOWING EXPOSURE TO
0 6 -BENZYLGUANINE WITH OR WITHOUT STREPTOZOTOCIN ENHANCES
1,3 BIS(2-CHLOROETHYL)-1 NITROSOUREA SENSITIVITY IN VITRO

Pretreatment of resistant cells with MGMT depleting
agents prior to CENU exposure successfully inactivates
MGMT, enhances DNA cross-link formation, and increases
cytotoxicity (Zlotogorski and Erickson, 1984; Dolan et
al., 1986; Dolan et al., 1990 a,b).

However, recent

observations suggested that maximal sensitization of CENU
resistant cells might require a more extended depletion
of MGMT following BCNU (Dolan et al., 1990; Gerson et
al., 1993).

The observation that the DNA interstrand

cross-link precursor 0 6 , N1 ethanoguanine is stable for
greater than 8 hr following CENU removal, suggests the
potential for cross-linking exists for extended periods
(Brent, 1985b).

Indeed, cross-links produced by several

CENU continue to form for 6-12 hr post-drug exposure and
persist for at least 24 hr in the MGMT deficient cell
lines (Ewig and Kohn, 1977; Erickson et al., 1980a).
Furthermore, when BG is employed as the BCNU resistance
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modulator, optimal enhancement of BCNU cytotoxicity
requires pre- and post-BCNU exposure of cells to BG
(Dolan et al., 1990; Gerson et al., 1993).

The

administration of BG following BCNU treatment may
inactivate nascent MGMT molecules.

Additionally, this

inactivation could prevent the repair of the stable
cross-link precursors (Gerson et al., 1993).

Therefore,

inactivation of MGMT for prolonged periods throughout the
time-course of cross-link formation would be expected to
maximize cross-link formation and cytotoxicity in MGMT
expressing cells.

However, no attempt has been made to

compare the enhancement of CENU cytotoxicity produced by
a single dose of BG with repeated administration of BG,
and thereby substantiate the aforementioned conclusions.
Therefore, the experiments described in this chapter
attempt to determine whether extended depletion of MGMT
activity is required for maximal enhancement of BCNU
cytotoxicity by BG or STZ in resistant cells.
In this chapter two pretreatment protocols were used
to examine whether extended depletion of MGMT was
required to maximize BCNU cytotoxicity.

The enhancement

of BCNU cytotoxicity and the recovery of MGMT activity
were measured following BG (10-100 µM)

and the

combination of BG (10 µM) and STZ (1.0 mM) in vitro.

In

the three drug combination of BG+STZ+BCNU, BG can deplete
MGMT allowing a greater number of STZ induced 0 6 -
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methylguanine lesions to form which can deplete MGMT for
an extended period.

The combination of BG+STZ produced a

more extended depletion of MGMT for 24 hr and a greater
enhancement of BCNU cytotoxicity than when BG or STZ were
used alone.

If the mechanism by which STZ increased

BG+BCNU cytotoxicity was by producing a more prolonged
depletion of MGMT, then higher doses of BG (10-100 µM)
which can deplete MGMT for 24 hr should also produce a
comparable enhancement of BCNU cytotoxicity.

A 100 µM

dose of BG produced complete inactivation of MGMT for
greater than 24 hr and the greatest enhancement of BCNU
cytotoxicity.

The studies suggest that the greatest BCNU

sensitization is reached when MGMT activity was depleted
prior to, and for at least 24 hours following BCNU
administration.

Moreover, these data suggest that the

design of clinical strategies targeting MGMT inactivation
should consider prolonged inhibition of MGMT activity to
increase the likelihood of anti-tumor responses.
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Materials and Methods

Cell Culture

HT-29 cells were cultured in Eagle's minimum essential
medium, supplemented with 10% bovine calf serum, 62.5 mM
HEPES buffer, 1 mM glutamine, 1 mM sodium pyruvate, 1 X
vitamin B12, 1 X non-essential amino acids (Hazelton) and
0.05 mg/ml gentamicin.

Cells were maintained in log

phase at 37°C in 95% air, 5% C0 2 atmosphere.

Colony Formation Assay

HT-29 cells were seeded at 150, 300, 1000, 3000, and
10,000 cells per T-25 mm 3 flask and incubated for 11-14 hr
to allow for complete attachment.

When testing the

cytotoxicity of the various combinations of BG, STZ, and
BCNU, triplicate flasks were individually treated with
BG, STZ and/or BCNU.

BG, STZ, and BCNU were dissolved in

dimethylsulfoxide, 0.9% NaCl, and 95% ethanol,
respectively.

The administration of dimethylsulfoxide

(1.0%) for 3 hr, or ethanol (1.0%) for 1 hr did not
produce greater than 2-3 % inhibition of colony
formation.

Cells were cumulatively exposed to BG for 3

hr, STZ for 2 hr, and BCNU for 1 hr.

In assessing the

cytotoxicity induced by BG+BCNU, cells were treated with
BG (10-lOOµM)

for 2 hr prior to a 1 hr exposure to BCNU.

Following treatment, drug containing medium was aspirated
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and replaced with fresh medium.

After 9-10 days, cells

were fixed in 100 % methanol, stained with a buffer
containing 2.31 mg/ml methylene blue, 2.5 rnM Na 2 HP0 4 ,
mM KH 2 P04 , and colonies were counted.

l.33

The survival values

plotted for the combinations of BG+BCNU, STZ+BCNU, and
BG+STZ+BCNU were normalized to BG, STZ and BG+STZ alone
induced cell killing.

Survival curves show the mean and

the standard deviation of three or more independent
experiments.

A minimum of triplicate determination of

cytotoxicity were made within each experiment.

Measurement of MGMT activity

The assay for MGMT activity Used in this study was
developed by Wu et. al.

(1987) and subsequently modified

in our laboratory (Futscher et al., 1989; Pieper et al.,
1991) .

Cultured cells were resuspended at a

concentration of approximately 3x10 7 cells/ml in assay
buffer (50 mM Tris pH 8, 1 mM DTT, 1 rnM EDTA, 5%
glycerol), quickly frozen in dry ice, and stored at -80°C
for subsequent measurement of MGMT activity.

The effects

of freezing and thawing of cells on MGMT activity will be
discussed below.
Due to exonuclease activity of the Klenow fragment of
DNA polymerase, the radiolabelling of the 0 6 -methylguanine
containing oligomer used in this study was catalyzed by
the Stoffel fragment of the Taq DNA polymerase.

The 18
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base pair oligomer containing an 0 6 -methylguanine lesion
was radiolabelled by filling in the 3' recessed end with
thymidine 5'- [a- 32 P] triphosphate (TTP)
Arlington Heights, IL).

(Amersham,

20 pmol of probe were incubated

with 10 units of Stoffel Taq DNA polymerase (Perkin
Elmer/Cetus, Norwalk, CT), 50 µCi of TTP (specific
activity 3000 Ci/mmol), 1.5 mM MgC1 2 ,
42°C for 1 hr.

lX Taq buffer at

The labeling reaction was terminated with

sequential extraction with phenol:chloroform:isoamyl
alcohol (PCI) and chloroform:isoamyl alcohol (CI).
Subsequently the DNA was precipitated in 70% ethanol,
73.0 mM sodium acetate and 20 µg oft-RNA.
In measuring MGMT activity, the radiolabelled oligomer
was incubated with 10 µg of total cellular protein (2 hr,
37°), PCI extracted, digested with Pvu II

(1 hr, 37°)

(Gibco BRL, Gaithersburg, MD), and electrophoresed on a
20% denaturing polyacrylamide gel.

The extent of

restriction enzyme cleavage of the radiolabelled 18 mer
to an 8 mer by Pvu II is directly proportional to MGMT
activity (Wu et al., 1987).

The radioactivity was

quantitated on a Betagen Betascope 603 blot analyzer.
The % probe cleaved
mer) X 100.

=

(CPMs 8 mer/ CPMs 18 mer + CPMs 8

Measurement of MGMT activity following

treatment with BG and STZ was normalized to untreated
control values.

Each data point represented the mean and

the standard deviation of three independent experiments.
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Freezing and thawing of cells did not result in
appreciable loss of MGMT activity.

Incubation of the

radiolabelled 18 mer with 25 µg of extracts freshly
prepared HT-29 extract resulted in 76.4 +/- 2.16 % probe
cleaved following Pvu II digestion.

Incubation of 25 µg

frozen cell extract for 24 hr at -80°C with the 0 6 methylguanine containing DNA resulted in 76.0 +/- 4.2 %
probe cleaved following Pvu II digestion.

Sl nuclease analysis of steady state MGMT mRNA levels
Labeling of the MGMT Sl probe

A PCR-generated MGMT cDNA was subcloned into the pGEM
-3Z

f- vector (Promega, Madison, Wi) and designated pMGMT

(Pieper et al., 1990).
10 units of Hinl I
agarose gel.

pMGMT (10 µg) was digested with

(Promega), and electrophoresed on a 1%

The 2.4 kb Hinl I fragment was excised from

the gel and purified by centrifugation through silanized
glass wool at 12,000 X g.

The filtrate was extracted

with phenol, and PCI, and then precipitated with ethanol.
The purified DNA was incubated with 5 units of Klenow DNA
polymerase (Promega) and 10 µCi of deoxycytidine 5'-[a32P] triphosphate (Amersham)
temperature for 15 min.

(6000 Ci/mmol) at room

The labelling reaction was

terminated by extracting once with PCI, once with CI
extraction, followed by precipitation with ethanol.
probe protects 570 nucleotides of MGMT mRNA.

This
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Sl nuclease protection assay

Excess labelled MGMT Sl probe was incubated with 40µg
of cytoplasmic RNA in 0.4 M NaCl, 40 mM 1,4piperazinediethanesulfonic acid (pH 6.8), 2 mM EDTA and
80% formamide.

The hybridization mixture was denatured

at 68°C for 15 min, immediately transferred to a 53°C
bath, and incubated >16 hr.

Subsequently, the nucleic

acid was digested with 400 U of Sl nuclease (Boehoringer
Mannheim, Philadelphia, PA) at 37°C for 1 hr, extracted
with PCI, precipitated with ethanol, and electrophoresed
on a 4% denaturing polyacrylamide gel.

The gel was

fixed in 10% acetic acid for 15 min, soaked in water for
15 min, dried at 80°c for 1 hr, and autoradiographed.
The probe was determined to be at least 100 fold in
excess of MGMT mRNA represented within 40 µg of HT-29 RNA
by comparing the intensity on the autoradiograph of 1:100
dilution of the radiolabelled probe alone to the
intensity of 100 fold greater amount of probe incubated
with 40 µg of RNA.

As determined by densitometric

analysis, the intensity of the probe alone control was
11.70 % greater in intensity than that was measured in 40

µg of RNA isolated from untreated HT-29 cell (Figure
3.6).

Therefore, the probe used in these experiments was

at least 100 fold in excess.
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Results

Dose dependent depletion of MGMT activity by BG.

To measure MGMT activity, a

32

P-end-labeled 18 base

pair oligomer containing an 0 6 -methylguanine lesion in the
Pvu II restriction site was incubated with 10 µg of whole
cell sonicate protein from control and BG treated HT-29
cells.

Repair of 0 6 -methylguanine by MGMT allowed Pvu II

cleavage of the oligomer to an 8 bp

32

P-labeled fragment.

The percentage of restriction enzyme cleavage was
directly proportional to MGMT activity (Wu et al., 1987).
The 10 µg of HT-29 cell extract was used in the
measurement of MGMT activity to maximize the sensitivity
of the assay.

This amount of protein was at the

saturation threshold of the assay (Appendix II) .

The

experiments described in this dissertation were designed
to measure decreases and not increases in MGMT activity
following drug treatment.

Therefore, small decreases in

MGMT activity could reliably be measured at the maximal
sensitivity of the assay in HT-29 cells using this
protein concentration.
(0.05-25 µM)

Exposure of HT-29 cells to BG

for 3 hr depleted MGMT activity in a dose

dependent fashion with an approximate dose for 50%
inhibition of 150 nM (Figure 3.1).

To insure maximal

inhibition of MGMT activity, a 10 µM dose of BG was
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Figure 3.1:
The effect of 0 6 -benzylguanine (BG) on MGMT activity in
HT-29 cells.

Cells were exposed for 3 hrs with 0.05-25 µM BG. 0 6 methylguanine containing probe was incubated with O µg
protein (lane 1),
O µg protein and digested with Pvu II
(lane 2), O µg protein and digested with Hae III (lane
3), 10 µg of total cellular protein from untreated (lane
4) or BG treated HT-29 cells (lanes 5-14) and digested
with Pvu II.
Extent of Pvu II digestion is proportional
to MGMT activity.

chosen for BCNU sensitization studies.
Comparison of the cytotoxicity induced by the combination
of BG+BCNU, STZ+BCNU, BG+STZ+BCNU.

Figure 3.2 illustrates the enhancement of BCNU
cytotoxicity by BG alone, STZ alone, or the combination
of BG+STZ.
(lOµM)

BG alone, STZ alone, or combination of BG

and the three doses of STZ were non-cytotoxic to

HT-29 cells (Table 3.1).

Therefore, the observed

enhancement of BCNU cytotoxicity by the various
pretreatment regimen was indeed synergistic.

Treatment

of HT-29 cells with 10 µM BG for 2 hr prior to a 1 hr
exposure to BCNU resulted in an increase in the toxicity
of lOOµM BCNU by approximately 0.5 log (Figure 3.2).
Administration of STZ at the non-toxic doses of 0.25-1.0
mM for 2 hr prior to BCNU exposure did not appreciably
modify BCNU cytotoxicity.

However, the addition of STZ

at the non-toxic doses of 0.25-1.0 mM to BG+BCNU
increased cytotoxicity in a dose dependent manner.
cells were exposed to BG (10 µM)

HT-29

for 1 hr, followed by

STZ [0.25 mM (A), 0.5 mM (B), 1.0 mM (C)]

for 1 hr, and

subsequently to a 1 hr exposure to BCNU.

These cells

received a 3 hr, 2 hr, 1 hr, exposure to BG, STZ, and
BCNU, respectively.

The addition of non-cytotoxic doses

of STZ (0.25, 0.5, 1.0 mM) to BG+BCNU resulted in
approximately 0.5-1.0 additional log enhancement of
BG+BCNU cytotoxicity.

The enhancement of BCNU
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Figure 3.2:
Comparison of the cytotoxicity induced by BG+BCNU, STZ+BCNU, or BG+STZ+BCNU.

HT-29 cells were treated with BCNU alone, or STZ (0.25, 0.50, 1.0 mM) + BCNU, or
BG (10 µM)+BCNU, or BG (10 µM) + STZ (0.25, 0.50, 1.0 mM) + BCNU.
Cells were
exposed to BG for 2 hrs and STZ for 1 hr prior to a 1 hr exposure to BCNU.
Identical survival curves for BCNU alone and BG+BCNU are reproduced in panels A, B
and c.
Panel A, B, and C, illustrate the enhancement of BG+BCNU cytotoxicity by
STZ at 0.25, 0.5, and 1.0 mM respectively.
Each data point represents the mean
and the standard deviation of three or more independent experiments. However, the
data point depicting the cytotoxicity produced by BG(lO µM) + STZ (1 mM) + BCNU
(100 µM) represents the mean of two independent experiments.
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Table 3.1:
Cell survival• following the various pretreatment regimens
used to enhance BCNU cytotoxicity

% Survival
BG
STZ
STZ
STZ

(10.0
(0.25
(0.50
(1. 00

BG
STZ
BG
STZ
BG
STZ

(10.0
(0.25
(10. 0
(0.50
(10.0
(1. 00

µM) b
mM)b
mM) b
mM) b
µM)

92.10
108.2
112.2
107.9

107.3 +/- 6.80

+
104.1 +/- 1.10

mM) c

µM)
mM) c

6.50
11. 6
17.2
12.7

+

mM) c

µM)

+/+/+/+/-

+
102.1 +/- 11. 9

a The survival values reported in this table indicate the
percentage of cells surviving +/- the standard deviation
after treatment with the various regimens. b The
cytotoxicity scores for STZ, BG alone are normalized to
untreated control values. c The combination cytotoxicity
values are normalized to scores obtained with BG alone,
and therefore reflect the cytotoxicity produced by STZ
when combined with BG.
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cytotoxicities, as reflected in the doses of BCNU
required to kill 90 % of seeded cells (IC90), is
illustrated in Table 3.2.

The addition of STZ at a dose

of 1.0 mM to the BG+BCNU regimen resulted in 1.86 fold
reduction in IC90 dose of BCNU.

Resynthesis of MGMT activity following treatment with BG,
STZ, and BG+STZ.
When STZ was used as the sole modulator of CENU
resistance, the formation of BCNU induced interstrand
cross-links and the enhancement of cytotoxicity were
related to the regeneration rate of MGMT activity
(Erickson et al., 1988; Pieper et al 1991).

As the

interval between STZ and CENU was increased, MGMT
activity recovered, and the potentiation of cross-link
formation and cytotoxicity decreased.

These data suggest

that resynthesis of MGMT following STZ might be an
important determinant in CENU resistance.

Based on these

observations, I hypothesized that the mechanism by which
STZ enhanced the toxicity of BG+BCNU was by producing a
more extended depletion of MGMT.

Figure 3.3 illustrates

the regeneration of MGMT activity following treatment of
cells with BG (10 µM), or STZ (1.0 mM), or BG+STZ.
Adhering to the treatment strategy used in the survival
assays, HT-29 cells were exposed to BG for 3 hr and STZ
for 2 hr.
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Table 3.2:
The IC90 dosesa of BCNU after treatment with BG, STZ, and
the combination of BG+STZ

BCNU alone

> 150 µM

BCNU +
BG ( 10. 0 µM)

117.5 µM

BCNU +
BG
(10.0 µM) +
STZ (0.25 mM)

92.5 µM

BCNU +
BG
(10.0 µM) +
STZ (0.50 mM)

82.5 µM

BCNU +
BG
( 1 0 . 0 µM) +
STZ (1.00 mM)

63.1 µM

a The concentration of BCNU required to inhibit the growth
of 90 % of seeded cells. The values depicted in this
table were extrapolated from the data illustrated in
figure 3.2.
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Figure 3.3:
MGMT activity in HT-29 cells following treatment with BG
alone (10 µM), or STZ alone (1.0 mM), or BG (10 µM) + STZ
(1.0 mM).

Following exposure of cells to BG alone for 3 hrs, STZ
alone for 2 hrs or the combination of BG + STZ, drug
containing medium was aspirated and replaced with fresh
media.
Cells were harvested O hr, 3 hr, 6 hr, 12 hr, 24
hr following drug removal. Panel A depicts MGMT activity
in HT-29 cells following drug treatment. Quantitation of
the results within panel A is shown in panel B. MGMT
activity is expressed as a percentage of activity
measured in untreated HT-29 cells. Each data point
represents the mean and the standard deviation of three
independent experiments.
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Subsequently, the drug containing medium was
aspirated, replaced with fresh media, and the cells were
allowed to recover for 0, 3, 6, 12, 24 hr following drug
removal.

At each time point, cells were harvested to

assess MGMT activity (Figure 3.3 A,B) and mRNA levels
(Figure 3.6).

Cells exposed to 1 mM STZ alone gradually

recovered MGMT activity reaching near control levels by
24 hr.

In contrast, cells exposed to BG (10 µM)

recovered approximately 15% of control activity within 6
hr, and essentially remained at that level through 24 hr.
Upon sequenced administration of BG and STZ, MGMT
activity was completely inhibited essentially for 24 hr.
Because the prolonged depletion of MGMT activity produced
by BG+STZ through 24 hr resulted in greater enhancement
of BCNU cytotoxicity than BG or STZ alone, it is
suggested that prolonged depletion of MGMT activity is
required to maximize BCNU cytotoxicity.
Effect of increased doses of BG on BCNU cytotoxicity and
recovery of MGMT activity
To further explore whether extended depletion of MGMT
is an important determinant in BCNU resistance, the
recovery of MGMT activity and the potentiation of BCNU
cytotoxicity by BG at doses greater than 10 µM were
examined (Figure 3.4).

If the extended depletion

provided by the addition of STZ to the 10 µM dose of BG
was indeed responsible for the greater cytotoxicity, then
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Figure 3.4:
Effect of 10-100 µM BG on the potentiation of BCNU
cytotoxicity in HT-29 cells

Cells were treated with 10-100 µM BG for 2 hr prior to a
1 hr exposure to BCNU. Drug containing medium was
removed and replaced with fresh medium.
Each data point
represents the mean and the standard deviation of results
from three independent experiments. However, the data
point depicting the cytotoxicity produced by the BG
(lOOµM) + BCNU (lOOµM) represents the mean of two
independent experiments.
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Figure 3.5:
MGMT activity in HT-29 cells following treatment with BG
(10-lOOµM) .

Cells were treated with BG (10-100 µM) for 3 hr,
replaced with fresh medium, and harvested at 0, 3, 6, 9,
12, 24, and 48 hr after drug treatment.
Panel A
illustrates the MGMT activity in HT-29 cells following
treatment with 0, 10, 25, 50, and 100 µM BG. Within each
quadrant of panel A, lanes 1 through 7 represent MGMT
activity at 0, 3, 6, 9, 12, 24, 48 hr following BG
removal. Panel B represents quantitation of results
within panels A, where MGMT activity is expressed as a
percentage of MGMT activity within untreated HT-29 cells.
Each data point represents the mean and the standard
deviation of three independent experiments.
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increased doses of BG which deplete MGMT for an extended
period should produce comparable cytotoxicity. When HT-29
cells were pretreated for 2 hr with 10-100 µM BG and
subsequently challenged with BCNU, the potentiation of
BCNU-induced cell kill increased in a dose dependent
fashion (Figure 3.4). When the recovery of MGMT activity
was

measured following exposure to 10-100 µM BG, MGMT

activity was also inhibited in a dose and time dependent
fashion (Figure 3.5).

At a 100 µM dose of BG, which

completely depleted MGMT for 48 hr, greater than 3 logs
of BCNU induced cell kill was observed.

These results

further supported the hypothesis that the extended
depletion of MGMT activity was required for maximal
enhancement of BCNU cytotoxicity.
Effect of prolonged depletion of MGMT activity on steady
state MGMT mRNA levels

The steady state MGMT mRNA levels did not change
following treatment with STZ (Pieper et al., 1991). To
examine whether prolonged depletion of MGMT activity
affected the steady state MGMT mRNA levels, expression of
the MGMT message was measured using an Sl nuclease
protection assay.

As illustrated in figure 3.6, when

cells were treated with STZ alone, BG alone, or the
combination which depleted MGMT activity for up to 24 hr,
there was no change in steady state mRNA levels.
Densitometric analysis indicated that there was no more
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than 1.30 % difference between any of the treatment
groups and untreated control.

Additionally, in HT-29

cells depleted of MGMT activity for 48 hr with lOOµM BG,
MGMT mRNA levels were unaltered (Figure 3.7).
Quantitation of these results demonstrated that there was
no greater than 14.3 % difference between measurements
made in control and BG treated cells.
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Figure 3.6:
Steady state mRNA levels following BG (10 µM), STZ (1 mM) or BG+STZ in HT-29
cells.
Cells collected in the MGMT regeneration experiments were split for the
determination of MGMT activity and mRNA levels.
40 µg of cytoplasmic RNA from
treated and untreated HT-29 cells were hybridized with excess probe and digested
with Sl nuclease resulting in the correct 570 nucleotide protection of the MGMT
mRNA.
Lane designations proceeding from left to right are the following: lane 1,
molecular size markers; lane 2, 1:100 dilution of undigested Sl probe; lane 3,
level of MGMT mRNA in untreated cells; lanes 4-8, mRNA levels in BG (10 µM)
treated cells, lanes 9-13, mRNA levels in cells treated with STZ (1 mM), lanes 1418, mRNA levels in cells treated with the combination of BG+STZ.
The numbers
indicated above lanes 4-18 depict the time of cell harvest in hours following drug
removal.
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Figure 3.7:
Steady state MGMT mRNA levels following a 100 µM ·dose of
BG

Lane 1 represents the levels of mRNA in untreated HT-29
cells. Lanes 2-8 represents the level of MGMT mRNA from
cells treated with BG at a dose of 100 µM for 3 hr and
harvested at the indicated times (in hours) .
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However, this recovery could be prevented for 24 hr by
the addition of a 1.0 mM dose of STZ, or for 48 hr by
The prolonged

increasing the dose of BG to 100 µM.

inhibition of MGMT produced by either STZ addition, or by
BG (lOOµM)

resulted in a greater enhancement of BCNU

cytotoxicity than the lOµM dose of BG.

These

observations may be explained in the following fashion.
When STZ was added to BG (lOµM),

the STZ induced 0 6 -

methylguanine lesions persisted in DNA providing
substrates for MGMT, and resulted in the repair-mediated
inactivation of the protein for prolonged periods.
increasing the dose of BG to lOOµM,

By

the residual amounts

of BG remaining within cells, after drug removal,
probably provided ample concentrations of the compound to
inactivate MGMT for extended periods. As a consequence of
this prolonged inactivation, the repair of the CENUinduced chloroethyl monoadducts was prevented, resulting
in increased levels of interstrand cross-links, and BCNU
cytotoxicity.

Collectively, the data suggest that

extended depletion of MGMT activity is an important
determinant in the reversal of CENU resistance, and that
chemotherapeutic regimens targeting the inactivation of
MGMT activity should be optimized such that MGMT activity
is depleted for prolonged periods following CENU
administration.
Pieper et al.

(1991) observed that the resynthesis of
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MGMT activity after treatment with STZ was not
accompanied by changes in steady state MGMT mRNA levels.
In order to ascertain whether a sustained inhibition of
MGMT activity would induce a compensatory change in mRNA
levels, a sensitive Sl nuclease protection assay was
developed to measure changes in mRNA levels.

There was

no change in steady state mRNA levels when MGMT activity
was depleted for 24 hr with the combination of BG+STZ, or
for 48 hr with lOOµM BG.

These data demonstrated that

during the period of prolonged depletion of MGMT
activity, the expression of MGMT mRNA was not inducible.
The observed regeneration of MGMT activity following STZ
or BG treatment was probably the result of a slow nascent
translation of steady state MGMT mRNA because MGMT was
not reactivated after alkyl transfer (Yarosh et al.,
1986), and because MGMT repletion was dependent on RNA
and protein synthesis (Yarosh et al., 1986; Gerson, et
al., 1988).
Additionally, STZ mediated reversal of CENU
resistance necessitated a 2.5 mM dose of STZ prior to
BCNU administration in vitro (Futscher et al., 1989).
Because 2.5-10 fold lower doses of STZ (0.25 mM-1.0 mM)
when combined with BG+BCNU effectively sensitized
resistant cells in vitro, a clinical regimen using
reduced doses of STZ in conjunction with BG+BCNU might
attenuate the clinical toxicity observed in the STZ+BCNU
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clinical trial

(Micetich et al., 1992).

If BG were to be

used in combination with STZ, then a greater and
prolonged inhibition of MGMT activity could be achieved.
Moreover, the combined use of BG and STZ as cooperative
modulators of CENU resistance could increase the
possibility of an anti-tumor response compared to the use
of either agent alone.

The conclusions made in this

chapter are further tested in the following chapter where
the enhancement of BCNU cytotoxicity is examined under
conditions of complete inhibition, partial or complete
recovery of MGMT activity by 24 hr.
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CHAPTER IV

EXTENDED DEPLETION OF 0 6 -METHYLGUANINE DNA
METHYLTRANSFERASE ACTIVITY FOLLOWING 0 6 -BENZYL-2'DEOXYGUANOSINE, OR 0 6 -BENZYLGUANINE COMBINED WITH
STREPTOZOTOCIN TREATMENT ENHANCES 1,3 BIS{2-CHLOROETHYL)l-NITROSOUREA CYTOTOXICITY

In the previous chapter, cells recovered only 10-15%
of control activity by 6 hr following treatment with a 10
µM dose of BG.

Increasing the dose of BG from 10 to 100

µM, or combining BG (lOµM) with STZ prevented this
recovery and produced a greater enhancement of BCNU
cytotoxicity.

From these data, it was suggested that

extended depletion of MGMT was required to maximally
enhance BCNU cytotoxicity in resistant cells.

However,

one may question whether the inhibition of only an
additional 10-15% of control MGMT activity for 24 hr by
the combination of BG+STZ can indeed explain the greater
enhancement of BCNU cytotoxicity.

Therefore, a repeated

wash protocol was developed to in order to more
definitively determine whether the regenerative rate of
MGMT activity is related to the enhancement of BCNU
cytotoxicity by BG or STZ.

The regeneration of MGMT
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activity in the VACO 6 cell line after BG administration
was dramatically altered by washing of cells with serum
containing media (Gerson et al., 1993).

Washed cells

rapidly recovered to control levels of MGMT activity,
whereas unwashed cells remained depleted (Gerson et al.,
1993).

In this chapter experiments will be presented

which use the repeated washing of cells to modulate the
recovery rate of MGMT activity, and to evaluate the
potentiation of BCNU cytotoxicity induced by regimens
which provide complete inhibition, partial or complete
recovery of MGMT activity by 24 hr.

The regenerative

rates of MGMT activity and the enhancement of BCNU
cytotoxicity with and without washing were measured
following BG, STZ, 0 6 -benzyl 2'-deoxyguanosine (dBG), and
the combinations of BG+STZ and dBG+STZ.
The recovery of MGMT after treatment with nucleoside
derivative of BG, dBG, was studied because it was
anticipated that this compound could potentially be
phosphorylated, trapped within the cells, unaffected by
washing, and continue to deplete MGMT for an extended
period.

However, as the studies presented in this

chapter demonstrate, this compound behaves similar to BG
in terms of MGMT inactivation and the potentiation of
BCNU cytotoxicity.

The data in this chapter further

confirm that extended deletion of MGMT is required for
maximal enhancement of BCNU cytotoxicity.
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Materials and Methods

Colony Formation Assay

HT-29 cells were seeded at densities ranging from 150100, 000 cells per T-75 mm 3 flask and incubated for 12 hr
to allow for complete attachment.

Cells were

cumulatively exposed to BG or dBG for 3 hr, STZ for 2 hr,
and BCNU for 1 hr.

Following treatment, drug containing

medium was aspirated, replaced with an equal volume of
fresh medium, and then cells were allowed to recover for
9-10 days.

Alternatively, the cells were repeatedly

washed with an equal volume of serum containing medium at
37°C.

A single wash cycle consisted of the following

manipulations: 1) Medium from each flask was aspirated
and replaced with fresh medium; 2) The flasks were gently
tumbled three times.
times.

This process was repeated four

After the final wash, cells were incubated for 9-

10 days, colony formation was assessed as described in
the previous chapter.

When testing the cytotoxicity of

the combinations of BG+BCNU, dBG+BCNU, STZ+BCNU, BCNU
induced cell kill was normalized to BG, dBG, STZ
controls, respectively. The cytotoxicity produced by the
various pretreatment regimens is illustrated in Table
4.1.

STZ, BG, dBG as single agents were not toxic to HT-

29 cells.

However, the combinations of BG+STZ or dBG+STZ

were mildly toxic.

In assessing the cytotoxicity of the
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Table 4.1:
Survivala following various pretreatment regimens used to
enhance BCNU cytotoxicity

% Survival
Without washing

With wash

STZ (2. 5 mM) b
(100 µM) b
BG
dBG (1. 0 mM) b

90.06 +/- 10.8
93.30 +/- 6.80
98.90 +/- 1. 80

91.52 +/- 10.6
90.30 +/- 6.00
92.46 +/- 14.8

BG
(100 µM) +
STZ (2. 5 mM) c

68.80 +/- 5.40

77.70 +/- 6.80

dBG (1. 0 mM) +
STZ (2. 5 mM) c

41.36 +/- 19.3

87.6 +/- 21. 6

a The survival values reported in this table indicate the
percentage of cells surviving +/- the standard deviation
after treatment with the various regimens. b The survival
scores for STZ, BG, or dBG alone were normalized to
untreated control values. c The survival values for the
combination of BG+STZ, or dBG+STZ were normalized to
scored obtained when cells were treated with BG or dBG
alone, and therefore reflect the cytotoxicity produced by
STZ when combined with BG or dBG.
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combinations of BG+STZ+BCNU and dBG+STZ+BCNU, the
cytotoxicity produced by these combinations was
normalized to the cell killing produced by BG+STZ and
dBG+STZ, respectively.

Therefore, the survival values

reflected the synergistic enhancement of BCNU
cytotoxicity by the various pre-treatment regimens.
Survival histograms show the mean and the standard
deviation of at least three independent experiments.

Measurement of MGMT activity

The protocol utilized in these experiments was similar
to that described in chapter 3 except for one
modification.

In measuring MGMT activity, the

radiolabelled 0 6 -methylguanine containing oligomer was
incubated with 10 µg of total cellular protein at 37°C
for 2 hr, digested with 40µg proteinase K (in the
presence of 1.0 % sodium dodecyl sulfate) for 1 hr at
45°C.

The proteinase K digestion was added to increase

the recovery of radioactivity.

After protein extraction,

the DNA was digested with Pvu II (Gibco BRL,
Gaithersburg, MD), and electrophoresed on a 20%
denaturing polyacrylamide gel.

The extent of restriction

enzyme cleavage of the radiolabelled 18 mer to an 8 mer
by Pvu II was directly proportional to MGMT activity (Wu
et al., 1987).

The radioactivity was quantitated on a

Betagen Betascope 603 blot analyzer.

The % probe cleaved
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= (CPMs 8 mer/ CPMs 18 mer + CPMs 8 mer) X 100.
Measurement of MGMT activity following treatment with BG,
dBG and/or STZ was normalized to untreated control
values.
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Results
Effects of the combination of BG+STZ on the recovery of
MGMT activity and potentiation of BCNU cytotoxicity.

Figure 4.1 illustrates the repletion of MGMT activity
in HT-29 cells following treatment with BG, STZ or the
combination of BG+STZ. Consistent with the observations
made in the VACO 6 cell line, the rate of repletion of
MGMT activity following BG (100 µM)
upon repeated washing.

treatment increased

Unwashed cells exhibited complete

depletion of MGMT activity for 24 hr.

In contrast,

washed cells gradually recovered MGMT activity and
reached near control levels by 24 hr.

The repletion

profile of MGMT activity following STZ treatment was
unaffected by washing. STZ at a dose of 2.5 mM completely
depleted MGMT activity for 12 hr after drug removal, and
cells gradually recovered to approximately 30% of control
activity by 24 hr.

When cells were treated with BG and

STZ in a sequential manner, the inactivation of MGMT
activity was complete for 24 hr, irrespective of washing.
These data suggested that when cells were depleted of
MGMT with BG, prior to STZ administration, a greater
number of STZ induced 0 6 -methylguanine lesions persisted
and continued to inactivate nascent MGMT molecules for
extended periods.
The striking differences in the repletion profile of
MGMT activity illustrated in Figure 4.1 predict dramatic
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Figure 4.1:
Differential recovery of MGMT activity following BG, STZ,
or the combination of BG and STZ.

HT-29 cells were exposed to BG (100 µM), STZ (2.5 mM)
alone, or sequentially with the combination.
Following
drug treatment, some treated cells were washed as
described in the "Materials and Methods" section. The
cells were harvested and analyzed for MGMT activity at
the indicated times after drug treatment with or without
washing.
Points, mean +/- SD of three independent
experiments.
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differences in the potentiation of BCNU cytotoxicity if
extended depletion of MGMT activity is required for
maximal enhancement of BCNU cytotoxicity.

The rank order

of the potentiation of BCNU cytotoxicity should inversely
follow the repletion rate of MGMT activity.

Those

regimens producing the most prolonged inhibition of MGMT
activity would be expected to produce the greatest
cytotoxicity.
Figure 4.2 illustrates the potentiation of BCNU
cytotoxicity by BG, STZ, and the combination of BG+STZ
with and without washing.

The combination of BG (100 µM)

+ BCNU (100 µM) without a wash produced approximately two
to three logs of synergistic cell kill.

However, cells

exposed to the identical regimen and washed after BCNU
exposure were dramatically less sensitive to the drug.
This treatment produced less than one log of BCNU (100
µM)

synergistic cell kill.

The sequential administration

of STZ followed by BCNU (100 µM) produced approximately 2
logs of synergistic cell kill.

STZ mediated potentiation

of BCNU cytotoxicity, similar to its repletion profile,
was unaffected by washing.
µM)

The combination of BG (100

+ STZ (2.5 mM) + BCNU (100 µM) produced 3-4 logs of

synergistic cell kill and this cytotoxicity was not
appreciably affected by washing.

These data demonstrate

that extended depletion of MGMT activity is required for
maximal enhancement of BCNU cytotoxicity because the pre
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Figure 4.2:
Differential potentiation of BCNU cytotoxicity by BG,
STZ, or BG+STZ, with or without washes.

Cells were sequentially exposed to BG and BCNU at a 2 hr
interval, STZ and BCNU or BG,STZ and BCNU at 1 hr
intervals with the indicated doses. The treatment and
wash protocols are detailed in the "Materials and
Methods" section. The survival histograms depict the
mean +/- SD of values obtained from three independent
experiments.
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treatment regimens which produced the slowest recovery
rate produced the greatest cytotoxicity.

Effects of the combination of dBG+STZ on the recovery of
MGMT activity and the potentiation of BCNU cytotoxicity.
To further test the hypothesis that extended depletion
of MGMT activity was required for optimal reversal of
BCNU resistance, the repletion of MGMT activity and
potentiation of BCNU cytotoxicity by the nucleoside
derivative of BG, dBG was examined. This compound has 10
fold lower affinity for MGMT (Moschel et al., 1992).
Figure 4.3 illustrates the repletion profile of dBG and
BG at their respective IC 100 doses (i.e. the dose
producing complete inactivation in the oligonucleotide
restriction assay) .

Unwashed HT-29 cells recovered

approximately 15% of control activity by 6 hr and
essentially remain at that level for 12 hr following
treatment with BG or dBG.

However, in a profile similar

to BG, the rate of repletion of MGMT activity following
dBG treatment increased with repeated washing.

Washed

cells recovered approximately 60 % of control activity by
12 hr. These data suggested that dBG similar to BG can be
readily washed out of cells.
When cells were treated with 0.1-1.0 mM dBG for 2 hr
prior to BCNU administration without a wash, BCNU
cytotoxicity increased in a dose dependent manner (Figure
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Figure 4.3:
Comparative repletion of MGMT activity in HT-29 cells treated with BG and dBG.

IC 100 doses of BG or dBG (lOµM and lOOµM, respectively) were administered to cells for 3
hr and cells were harvested at the indicated times after drug treatment. 0 6 methylguanine containing probe was incubated with 10 µg of total cellular protein from
untreated (lane 1), BG treated and unwashed (lanes 2-4), BG treated and washed (lanes 57), dBG treated and unwashed (lanes 8-10), dBG treated and washed (lanes 11-13) HT-29
cells. Extent of Pvu II cleavage of the 18 nucleotide fragment to an 8 nucleotide
fragment is directly proportional to MGMT activity.
The wash protocol is described in
the "materials and methods".
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Figure 4.4:
Potentiation of BCNU cytotoxicity by dBG

Cells were pretreated with dBG (0.1-1.0 mM) for 2 hr
prior to a 1 hr exposure to various doses of BCNU.
After BCNU treatment, drug containing medium was
aspirated, replaced with an equal volume of fresh medium,
and colony formation was assessed after 10 days.
Points,
mean and SD of survival values measured in 3 or more
replicate flasks.
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4.4).

This potentiation profile of BCNU cytotoxicity by

dBG was extremely similar to BG (10-100 µM)

mediated

enhancement described in the previous chapter.

This

observation was consistent with the 10 fold lower
affinity of dBG than BG for MGMT.

In order to enhance

BCNU cytotoxicity comparable to that produced by BG, 10
fold greater doses of dBG were required.

Measurement of

the repletion kinetics of MGMT activity following dBG
(0.1-1.0 mM) treatment (without a wash) revealed a modest
dose and time dependent inhibition of MGMT activity
(Figure 4.5).

The 1.0 mM dose of dBG produced sustained

inhibition of MGMT activity for 24 hr and the greatest
BCNU cytotoxicity.

These data suggested that extended

depletion of MGMT following dBG treatment is also
important in maximizing BCNU cytotoxicity.

However, the

activity measured in this experiment was extremely small.
Therefore, this hypothesis was further tested by using
dBG in a series of MGMT repletion and BCNU potentiation
experiments with washes.

Figure 4.6 illustrates the

recovery of MGMT activity following 1.0 mM dBG alone and
in combination with STZ with and without washes.

dBG

alone without a wash completely inactivated MGMT for 24
hr.

Upon repeated washing, the rate of recovery of MGMT

activity increased dramatically.

As previously shown,

the repletion of MGMT activity following STZ was
unaffected by washes.

The combination of dBG+STZ
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Figure 4.5:
MGMT activity in HT-29 cells following treatment with dBG
(100-1000 µ,M).

Cells were treated with BG (100-1000 µM) for 3 hr,
replaced with fresh medium, and harvested at 0, 3, 6, 12,
and 24 hr after drug treatment. These data are from a
single experiment.
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Figure 4.6:
Differential recovery of MGMT activity following dBG,
STZ, and the combination of dBG and STZ.

HT-29 cells were administered dBG (1.0 mM) for 3 hr, STZ
(2.5 mM) for 2 hr or the combination. Following drug
treatment, media was removed, replaced with fresh media
or repeatedly washed as described in the "Materials and
Methods".
Points represent the mean+/- standard
deviation of two independent experiments.
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produced sustained inhibition of MGMT activity
essentially for 24 hr, irrespective of washes.
Examination of the potentiation of BCNU cytotoxicity by
dBG with or without washes revealed the pattern of
reversal of BCNU resistance was very similar to that seen
with BG (Figure 4.7).

The combination of dBG (1.0 mM)

+

BCNU (100 µM) without a wash produced approximately 3
logs of synergistic cell kill.

Repeated washing of cells

drastically increased the recovery rate of MGMT activity
and decreased BCNU cytotoxicity.

When this recovery was

prevented for 24 hr by the addition of STZ, the
combination produced three to four logs of synergistic
cytotoxicity at a 100 µM dose of BCNU.

These data

further demonstrated the importance of prolonged
depletion of MGMT activity in CENU resistance modulation.
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The protocol utilized is identical to that described in
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Discussion

The data presented within this chapter further confirm
that extended depletion of MGMT following BG, dBG, and
STZ was required to maximize BCNU in vitro.

The data

showed that pretreatment regimens producing the most
extended depletion of MGMT activity for 24 hr produced
the greatest enhancement of BCNU cytotoxicity.

The

recovery rate of MGMT activity following dBG or BG was
modulated by repeated washing of cells.

BG and dBG,

without washing, produced complete depletion of MGMT
activity for 24 hr and potentiated BCNU cytotoxicity by
about 3 logs.

The prolonged depletion resulted

presumably from residual BG or dBG remaining within
cells.

However, washing of cells following BG or dBG

administration increased the repletion rate of MGMT;
cells recovered to control levels of MGMT by 24 hr.
Under these conditions, the enhancement of BCNU
cytotoxicity was markedly diminished to less than one log
of synergistic cell kill.

STZ was combined with BG or

dBG to prevent this post-wash recovery of MGMT, and to
restore non-wash sensitivity.

The post-wash recovery of

MGMT activity following BG or dBG administration was
inhibited for 24 hr by the addition of STZ.

The

sequential exposure of BG followed by STZ, or dBG
followed by STZ, produced sustained inhibition of MGMT
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activity for 24 hr, irrespective of washing.

The

combination of BG+STZ+BCNU or dBG+STZ+BCNU produced
greater than 3 to 4 logs of synergistic cell kill with or
without washing.
The repletion profiles of the direct MGMT depleting
agents BG and dBG markedly differed from that of STZ
after repeated washing of cells.

BG and dBG produced

sustained inhibition of MGMT for 24 hr without washing,
whereas with washing MGMT gradually recovered to control
levels by 24 hr.

Because BG and dBG are lipophilic

molecules, repeated presentation of drug free medium to
cells probably facilitated the removal of the compounds
via passive diffusion.

With the resultant decrease in

intracellular concentrations of the free bases, MGMT
activity recovered at a faster rate.

In contrast, the

recovery rate of MGMT following STZ treatment was
unaffected by washing.

This result is consistent with

the mechanism by which STZ depletes MGMT.

STZ-induced 0 6 -

methylguanine lesions in DNA facilitate the repairmediated inactivation of MGMT (Brent, 1986).

Washing of

cells would not be expected to change the intracellular
concentration of this substrate, and therefore not affect
the regenerative rate of MGMT.
Dolan et al.

(1990a; 1991) suggested that optimal

reversal of BCNU resistance required cellular
administration of BG pre- and post-BCNU exposure because
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the presentation of BG to cells following BCNU
facilitated the inactivation of nascent MGMT molecules
(Yarosh, et al., 1986; Gerson et al., 1988) and thereby
increased BCNU sensitivity.
Gerson et al.,

Consistent with this notion,

(1993) suggested that prolonged depletion

of MGMT prevented the repair of the stable, cross-link
precursor 0 6 , N1 ethanoguanine.

Prevention of this repair

by BG post-BCNU administration could have increased the
accumulation of the cytotoxic DNA interstrand cross-links
(Gerson et al., 1993).
In BG or dBG treated and washed cells, MGMT activity
recovered and presumably repaired any persistent crosslink precursors, and thereby prevented the accumulation
of DNA interstrand cross-links.

This precursor repair

was probably attenuated by the addition of STZ to BG, or
dBG.

The sequential administration of a guanine analog

and STZ probably allowed a greater number of STZ induced
0 6 -methylguanine lesions in DNA to persist, providing
substrates which continued to deplete MGMT activity for
24 hr.

This greater extended depletion of MGMT probably

allowed an increased number of BCNU cross-links which
were responsible for greater cytotoxicity.
The kinetics of BCNU cross-link formation and removal
in CENU resistant cell lines depleted of MGMT have not
been measured, but the frequency of BCNU induced crosslinks did indeed increase when resistant cells were
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initially depleted of MGMT by STZ or BG (Futscher et al.,
1989; Mitchell et al., 1992).

However, these were static

determinations made at the estimated times of maximal
cross-linking (6 or 14 hr after drug treatment) .

In an

MGMT deficient cell line, BCNU, CCNU, CNU and
chlorozotocin induced cross-links continued to form for
6-12 hr after drug removal (Erickson et al., 1980a).

The

steady state level of cross-links beyond 12 hr could be
due to continual formation of interstrand cross-links and
repair by perhaps an excision repair mechanism (Swinnen
et al., 1991).

The potential for continuous cross-link

formation was suggested by the remarkable stability of
the cross-link precursor 0 6 , N1 ethanoguanine; this
intermediate was stable in DNA for greater than 8 hr
after drug removal (Brent et al., 1987).

Extended

depletion of MGMT might be required to maximize DNA
interstrand cross-links and cytotoxicity in CENU
resistant cells because MGMT reacted with this precursor,
resulted in the formation of an MGMT-DNA cross-link
instead of a DNA interstrand cross-link.

This hypothesis

might be tested by examining the kinetics of cross-link
formation under conditions of complete inhibition,
partial, and complete recovery of MGMT activity by 24 hr
in CENU resistant cells.
If extended depletion of MGMT was the sole determinant
for maximizing BCNU cytotoxicity, then all regimens which
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provided complete inhibition of MGMT for 24 hr should
have produced comparable cytotoxicities.

However, BG and

BG+STZ completely inhibited MGMT for 24 hr, but the
combination of BG+STZ+BCNU produced at least 1 log
greater cytotoxicity than BG+BCNU in an unwashed
situation.

Likewise, the combination of dBG+STZ

potentiated BCNU cytotoxicity greater than dBG alone.
The greater cytotoxicity produced by the addition of STZ
to BG+BCNU or dBG+BCNU regimen may be attributed to the
cytotoxic effects of STZ induced 0 6 -methylguanine lesions.
Day et al (1987) proposed that the 0 6 -methylguanine lesion
could trigger lethality by activating a type of mismatch
repair acting on the distortion in DNA created by the
inappropriate base pairing of 0 6 -methylguanine : cytosine.
Once this mismatch is detected, several bases in the
undamaged strand of DNA are incised and resynthesized
(Day et al., 1987).

The infidelity of the repair

polymerase could generate another mismatch across the 0 6 methylguanine lesion (Day et al., 1987).

The creation of

another mismatch may result in futile cycle of mismatch
repair, depleting nucleotide pools, and resulting in the
cytostatic effects of methylating agents (Day et al.,
1987; Kat et al., 1993).
Kaina et al.

(1991) demonstrated that the transfection

of the MGMT or ada complementary DNAs protected CHO cells
from the mutagenic, clastogenic and cytotoxic effects of
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MNNG, HeCNU, and the STZ parent compound MNU.

These data

indicate that 0 6 -methylguanine is indeed a cytotoxic
lesion and MGMT plays a pivotal role in preventing the
toxic effects mediated by this lesion.

The following

remarks are offered to explain the greater cytotoxicity
induced by the three-drug combinations (BG+STZ+BCNU and
dBG+STZ+BCNU) than any two drug regimen.

When MGMT was

initially depleted with BG or dBG, a greater number of
STZ induced 0 6 -methylguanine lesions would be expected to
form, act in concert with the toxic lesions produced by
BCNU, and thereby produce a greater potentiation of BCNU
cytotoxicity.

However, the cytotoxicities of the three-

drug combinations were normalized to cytotoxicities
induced by the combination of BG+STZ or dBG+STZ.
Whatever intrinsic lethality offered by the addition of
STZ would have been accounted for in the normalization
process.

One may speculate that the cytostatic response

mediated by the 0 6 -methylguanine lesion was greater in the
presence of BCNU induced DNA damage than in its absence.
If this speculation is correct, the three-drug
combination would be expected to produce greater
cytotoxicity than the non-STZ containing regimens.
Further experiments are clearly required to resolve this
issue.
Because the combined administration of the direct MGMT
depleting agents, dBG or BG, and the indirect depleting

85

agent, STZ, sensitized HT-29 cells to BCNU cytotoxicity
to a greater degree than modulation with a single agent,
the combined clinical testing of resistance modulators
with different modes of action might be justified.

In

chapter three, it was observed that the combination of
BG+STZ at 10 fold lower doses than used in this study,
effectively sensitized BCNU resistant cells.

A clinical

regimen utilizing a low dose of BG followed by a low dose
STZ might decrease the clinical toxicities observed in
the recent STZ+BCNU clinical trials (Micetich et al.,
1992).

This protocol may produce a more efficient

depletion of MGMT than the use of BG or STZ alone.

If

ample plasma concentrations of BG cannot be achieved to
produce sustained inhibition in tumors exhibiting high
levels of MGMT due to the limited solubility of the
compound, then repeated administration of BG, or the
addition of STZ to a BG+BCNU regimen might be necessary.
The addition of STZ to a BG+BCNU regimen could result in
extended depletion of MGMT, and the STZ-induced DNA
damage could increase the tumor cell lesion burden,
thereby increasing the possibility of anti-tumor
responses.

In the following chapter, the enhancement of

BCNU cytotoxicity by the combination of BG+STZ is further
tested in an in vivo anti-tumor model in order to
determine the potential clinical utility of the
sequential administration of BG, STZ, and BCNU.
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CHAPTER V

ANTI-NEOPLASTIC ACTIVITY OF SEQUENCED ADMINISTRATION OF
BG, STZ, AND BCNU IN VITRO AND IN VIVO

In the previous chapters, the combined administration
of BG+STZ produced an extended depletion of MGMT for 24
hr and a greater enhancement of BCNU cytotoxicity than
either BG or STZ.

Based on these in vitro observations,

the clinical testing of this combination was recommended.
In order to further justify this recommendation, the
effectiveness of extended depletion of MGMT for 24 hr on
the enhancement of BCNU anti-tumor activity was examined
in vivo with the combination of BG and STZ.

The

experiments presented in this chapter used the resistant
human glioblastoma SF767 cells grown in culture, and as
subcutaneous xenografts in nude mice.

The feasibility of

the potential clinical use of the three-combination was
tested in vivo with the subcutaneous xenograft model
because this anti-tumor model more reliably predicts the
clinical utility of novel chemotherapeutic regimens than
in vitro cytotoxicity assays.
SF767 astrocytoma cell line was selected on basis of
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the rationale developed by Mitchell et al.

(1992).

These

investigators suggested that, because rodent tissue
generally contained lower MGMT activity than their human
equivalents, the use of a human xenograft with comparable
levels of MGMT to host tissues may be more predictive of
the clinical effectiveness of a potential
chemotherapeutic regimen.

Therefore, the SF767 cell

line, which contains approximately equivalent MGMT
activity to mouse liver (Mitchell et al., 1992; Figure
5.5), was used for the in vivo testing of the combination
of BG+STZ+BCNU.
Furthermore, the growth rate of SF767 xenografts was
significantly inhibited by i.p. administration of BG (80
mg/kg)

followed by BCNU (20 mg/kg) without appreciable

animal toxicity (i.e. in terms of animal death and nadir
in weight loss)

(Mitchell et al., 1992).

STZ was added

to this treatment protocol in order to examine whether
the combination of BG+STZ would produce

a more extended

depletion of MGMT activity and a greater enhancement of
BCNU anti-tumor activity than that obtained with BG in
cultured SF767 cells and xenografts.

88

Materials and Methods

Colony Formation Assay
The human glioma cell line, SF767, was kindly provided
by The Brain Tumor Research Center, University of
California at San Francisco. SF767 cells were cultured in
Eagle's minimum essential medium, supplemented with 10%
bovine calf serum, 62.5 mM HEPES buffer, 1 mM glutamine,
1 mM sodium pyruvate, 1 X vitamin B12, 1 X non-essential
amino acids, and 0.05 mg/ml gentamicin. Cells were
maintained in log phase at 37°C in 95% air, 5% C0 2
atmosphere.

The cytotoxicity assay used in this chapter

was identical to that described in chapter 3.

Animal studies
Female NIH Swiss nude mice and NIH Swiss normal mice
were purchased from Frederick Cancer Research and
Development Center (Frederick, MD) .

Animals were housed

in a sterile environment and provided with food and water

ad libitum.

The nude mice were subcutaneously injected

in the flank region with 7-10 x 10 6 SF767 cells.

In tumor

growth studies, animals were randomized and treated with
various regimens when tumor volumes reached 30-112 mm 3 •
Animal weights and tumor volumes were measured twice per
week.

Additionally, animals were euthanized when tumor
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exceeded 1500 mm 3 •

Tumor volumes were calculated using

the formula: Length X Width 2 X 0.53.

In the MGMT

repletion studies, tumor volumes ranged from 200 to 400
mm 3 at the time of treatment.

BG, STZ, and BCNU were

dissolved in 10% cremophor EL, normal saline, and 10%
ethanol/90% normal saline, respectively.

At various

times following drug exposure, mice were euthanized via
cervical dislocation.

The tumors and organs were

dissected, quickly frozen in liquid nitrogen, and stored
at -80°C for subsequent MGMT analysis.

Measurement of MGMT activity

The preparation of MGMT extracts and measurement of
MGMT activity from cultured cells have been previously
described in chapters four and five.

In preparing MGMT

extracts from SF767 xenografts and organs, the dissected
tumors and organs which had been frozen at -80°C were
thawed and homogenized for 30 sec in approximately 3 ml/g
wet tissue weight of homogenizing buffer containing 50 mM
Tris, 5 mM DTT, 0.1 mM EDTA, pH 8 with an OMNI
International 1000 tissue homogenizer.

The homogenate

was centrifuged for 5 min at 12,000X g at 4°C.

The cell

pellet was reconstituted to approximately 1 ml/g of
original wet tissue weight, homogenized for 15 sec and
sonicated for an additional 30 sec.

Both supernatants

were combined and centrifuged at 12,000 X g at 4°C for 30
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min.

Total cellular protein concentration of the

supernatant was quantitated utilizing the Bradford micro
protein assay (Bio Rad, Richmond, CA.).
activity, a

32

To measure MGMT

P-labeled 18 base pair oligomer containing

an 0 6 -methylguanine lesion in the Pvu II restriction site
was incubated with lOµg or 25µg of whole cell sonicate
protein in the homogenizing buffer for 2 hr.

After the

incubation, the protein was digested with 40µg of
proteinase K in the presence of 1% sodium dodecyl sulfate
for 1 hr at 45°C.

The DNA was purified using a single

PCI extraction and ethanol precipitation.

The DNA was

subsequently digested with 10 units of Pvu II,
electrophoresed on a 20% denaturing polyacrylamide gel
and autoradiographed.

Repair of 0 6 -methylguanine by MGMT

allows Pvu II cleavage of the oligomer to an 8 base pair
32

P-labeled fragment.

The percentage of restriction

enzyme cleavage is directly proportional to MGMT
activity.

The radioactivity was quantitated using the

Betagen betascope 603 blot analyzer.

% probe cleaved=

(CPMs of 8 mer/CPMs of 18 mer+ CPMs of 8 mer) x 100.
The values of MGMT activity measured after drug treatment
was normalized to untreated control values.
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Results

Inactivation of MGMT activity and potentiation of BCNU
cytotoxicity by the following pretreatment regimens in
SF767 cells; BG, STZ, and the combination of BG+STZ

The human astrocytoma cell line SF767 contains
appreciable levels of MGMT and is consequently highly
resistant to the cytotoxic effects of CENUs (Dolan et
al., 1991).

The repletion kinetics of MGMT activity

following treatment with BG (lOµM), STZ (0.5mM), and the
combination of BG+STZ is illustrated in Figure 5.1.

MGMT

activity was completely inactivated immediately following
BG exposure.

Thereafter, cells recovered no greater than

15% of control MGMT activity through 24 hr.

Following

STZ treatment, MGMT was inactivated by greater than 90%
of control activity at O hr, and recovered to
approximately 60% of control activity by 24 hr.

However,

sequential administration of BG and STZ produced near
complete inactivation of MGMT activity through 24 hr.
The combination of BG+STZ produced a greater and a more
extended inhibition of MGMT activity than either agent
alone.
Figure 5.2 illustrates the potentiation of BCNU
cytotoxicity by the various pretreatment regimens. BG,
STZ, or the combination of BG+STZ were essentially non
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Figure 5.1:
Inactivation and recovery of MGMT activity in SF767 cells
in vitro.
SF767 cells were treated with BG (10 µM) for three hours,
STZ (0.5 rnM) for two hours or the combination. After the
three hours the drug containing medium was removed and
replaced with fresh medium. The illustrated times refer
to the time of cell harvest following drug removal. MGMT
activity is expressed as a percentage of activity in
untreated SF767 cells.
Points represent the mean +/- SD
of three independent experiments.
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Figure 5.2:
Comparison of the cytotoxicity induced by BG+BCNU,
STZ+BCNU, or BG+STZ+BCNU in vitro.

SF767 cells were treated with BCNU (50-100 µM) alone, or
STZ (0.50 mM) + BCNU (50-100 µM), or BG (10 µM) + BCNU
(50-100 µM), or BG (10 µM) + STZ (0.50 mM) + BCNU (50-100
µM) . Cells were exposed to BG for 2 hr and STZ for 1 hr
prior to a 1 hr exposure to BCNU. Each data point
represents the mean +/- SD of three independent
experiments.
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Table 5.1:
Survivala following the various pretreatment regimens used
to enhance BCNU cytotoxicity in SF767 cells

% Survival
BG

(10.0 µM) b

96.60 +/- 0.63

mM)b

87.37 +/- 5.44

STZ (0.50

BG
(10.0 µM) +
STZ (0.50 mM) c

87.19 +/- 6.24

The survival values reported in this table indicate the
percentage of cells surviving +/- the standard deviation
after treatment with the various regimens. b The
cytotoxicity scores for STZ, BG alone are normalized to
untreated control values. c The combination cytotoxicity
values are normalized to scores obtained with BG alone,
and therefore reflect the cytotoxicity produced by STZ
when combined with BG.
a
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toxic at the doses used in these studies (Table 5.1).
Cytotoxicities of BG+BCNU, STZ+BCNU, BG+STZ+BCNU were
normalized to BG, STZ, or BG+STZ cytotoxicity.
Therefore, the enhancement of BCNU cytotoxicity
illustrated in Figure 5.2 by the different pretreatment
regimens was synergistic.

The combinations of STZ+BCNU,

BG+BCNU, BG+STZ+BCNU at 100 µM dose of BCNU potentiated
cell killing by approximately 0.5, 1.0 and 2.0 logs,
respectively. The enhancement of BCNU cytotoxicity as
reflected in the decrease in the IC90 dose of BCNU, is
illustrated in Table 5.2.

The addition of STZ at a dose

of 0.5 mM to the BG+BCNU regimen resulted in a 22.9 %
reduction in the IC90 dose of BCNU. The combination of
BG+STZ, which produced extended depletion of MGMT
produced the greatest sensitization of SF767 cells to
BCNU cytotoxicity.

These observations were consistent

with the determinations made in HT-29 cells in that the
combination of BG+STZ produced a more extended depletion
of MGMT and a greater enhancement of BCNU cytotoxicity
than BG or STZ alone. These data demonstrate that the
requirement of extended depletion of MGMT in maximizing
BCNU cytotoxicity is not restricted to HT-29 cells.
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Table 5.2:
The IC90 doses• of BCNU when SF767 cells were treated with
the various pretreatment regimens

BCNU alone

> 100 µM

BCNU +
STZ (0.5

> 100 µM

mM)

BCNU +
BG (10.0 µM)
BCNU +
BG ( 10. 0 µM)
STZ (0.5 mM)

87.5 µM
+

67.7 µM

The concentration of BCNU required to reduce survival of
the seeded cells by 90%. The values depicted in this
table were extrapolated from the data illustrated in
figure 5.2.

a
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Effects of the combination of BG+STZ on the inactivation
of MGMT activity and the enhancement of BCNU anti-tumor
activity in vivo.

The following series of experiments examined whether
the addition of STZ to the BG+BCNU regimen would produce
extended depletion of MGMT activity for 24 hr and greater
inhibition of tumor growth, or produce tumor regression
when compared to the combination of BG+BCNU alone.
Preliminary acute toxicity studies using female NIH Swiss
regular mice were performed to determine the maximally
tolerated dose of STZ in the three drug combination of
BG+STZ+BCNU (Table 5.3).

Animals were administered the

combinations of BG+BCNU or BG+STZ+BCNU i.p.

The dose BG

was fixed at 80 mg/kg. Animal were treated with BG
followed by BCNU at 15 or 20 mg/kg.

Alternatively,

animals were injected with BG followed by STZ (25-200
mg/kg) followed by the BCNU. The maximally tolerated
doses of the three drug combination were inferred to be
BG at 80 mg/kg, STZ at 100 mg/kg, and BCNU at 15 mg/kg
because these doses produced minimal weight loss and no
animal deaths, and because any further increases in the
dose of STZ, and/or BCNU resulted in animal deaths.
Therefore, the 80 mg/kg dose of BG and the 100 mg/kg dose
of STZ were used in MGMT repletion experiments and BCNU
anti-tumor experiments in female nude mice bearing SF767
xenografts.

Animals were injected with BG, STZ, or the
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Table 5.3:
Toxicities of BG+BCNU and BG+STZ+BCNU combinations
in normal NIH swiss female mice
Mice were sequentially administered BG, STZ, and/or BCNU
i.p. at one hour intervals. Animal weights were measured
twice weekly for 28 days.
Mean maximum
wt loss (%)

Combination (mg/kg)

# of animal
deaths a

BG
BG
BG
BG
BG

(80)+
( 80) +
( 80) +
( 80) +
( 80) +

BCNU
BCNU
BCNU
BCNU
BCNU

(15)
(15)+
( 15) +
( 15) +
( 15) +

( 25)
( 5 0)
( 100)
( 2 00)

7.50
13.0
11. 0
5.90
10.5

0/4
1/4
0/4
0/4
4/12b

BG
BG
BG
BG

( 80)
( 80)
( 80)
( 80)

BCNU
BCNU
BCNU
BCNU

( 2 0)
(20) + STZ (25)
(20) + STZ ( 5 0)
(20) + STZ ( 100)

15.6
13.4
18.1
22.8

2/4
1/4
2/4
3/4

+
+
+
+

STZ
STZ
STZ
STZ

aNumber of animal deaths/number of animals treated.
These
data reflected the number of spontaneous deaths and the
number of animals sacrificed following 20-25% reduction
in total body weight.
bSurvival through 14 days.
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Figure 5.3:
Repletion of MGMT activity in SF767 xenografts following
treatment with BG, STZ, or BG+STZ.

Mice carrying SF767 xenografts were administered 80 mg/kg
BG one hour prior to the administration of 100 mg/kg STZ
i.p. Animals were sacrificed at the indicated times. The
O hr time point refers to 3 and 2 hr following BG and STZ
treatment, respectively. MGMT activity was expressed as
a percentage of activity measured in untreated
xenografts.
Measurements of STZ alone at 0, 24, and 48
hr, BG and BG+STZ at the 0 and 6 hr time points represent
the mean MGMT activity of two animals. The remaining
data points represent the mean and SD of three animals.
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combination of both agents at one hour intervals and were
sacrificed at times illustrated in Figure 5.3.

Figure

5.3 illustrates the effectiveness of the combination of
BG and STZ on the inactivation and recovery of MGMT
activity in SF767 xenografts.

As a single agent, STZ

(100 mg/kg) did not appreciably affect MGMT activity in
the xenografts whereas, complete inhibition of MGMT
activity for 12 hr wasobserved following BG (80 mg/kg)
administration.

Thereafter, MGMT recovered to

approximately 40% of control levels by 24 hr.

Sequenced

administration of BG (80 mg/kg) and STZ (100 mg/kg)
produced a slower recovery rate of MGMT activity than BG
alone.

The combination produced near complete inhibition

of MGMT activity for 24 hr.

Thereafter, the tumors

recovered control levels of MGMT activity by 48 hr.
These data were consistent with the in vitro observations
in that the combination of BG+STZ produced extended
depletion of MGMT for nearly 24 hr.

These data further

suggest that the sequential administration of BG and STZ
probably allows a greater number of STZ induced 0 6 methylguanine lesions in DNA to persist and deplete MGMT
for 24 hr in the xenografts.

Nude mice bearing SF767

xenografts were sequentially administered the maximally
tolerated doses of BG, STZ, and BCNU to test whether this
three-drug combination would provide greater anti-tumor
activity than BG+BCNU.

Figure 5.4 illustrates the anti-

Figure 5.4:
Tumor growth inhibition assay utilizing subcutaneously implanted SF767 xenografts.

Nude mice carry the xenografts were injected i.p. with BG (80 mg/kg), STZ (100
mg/kg), and/or BCNU (15 mg/kg) at one hour intervals. Each data point represents
the mean percent change in tumor volumes of 5-9 animals. The individual tumor
volumes throughout the study were normalized to pretreatment values for each
individual tumor.
Panel A, B, and C depict the anti-tumor activity in animals
receiving the combination of STZ+BCNU, BG+BCNU, BG+STZ+BCNU, respectively. Within
panel D, the tumor growth curves of untreated, BCNU, BG+BCNU, STZ+BCNU,
BG+STZ+BCNU treated animals are reproduced for comparison.
Statistical analysis,
the data were analyzed with an multivariate ANOVA using repeated measures with a
post-hoc test of single degree of freedom contrast.
The analysis was performed
with the SYSTAT~ statistical package.
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tumor activity of all combinations of BG, STZ, and BCNU.
Panels A, B, and C depict the results of tumor growth
inhibition assays in animals receiving STZ+BCNU, BG+BCNU,
and BG+STZ+BCNU, respectively.

The combination of

STZ+BCNU produced significantly greater inhibition of
tumor growth on days 20 and 23
controls.

(p < 0.02) than untreated

However, BG which depleted xenograft MGMT for

12 hours produced significant inhibition of tumor growth
for 9-23 days relative to the untreated controls (p <
0.02).

These results are consistent with the

observations made by Mitchell et. al (1992) in that the
combination of BG+BCNU produced significant inhibition of
SF767 xenograft growth for greater than 20 days.
Similarly, the three drug combination of BG+STZ+BCNU also
significantly inhibited tumor growth for 23 days as
compared to the untreated controls (p < 0.01).

However,

tumor regressions, defined as reductions in tumor volume
over two consecutive measurements, were not observed in
any of the tumors treated with the various combinations.
In panel D, the tumor growth rates from untreated animals
and those treated with BCNU, STZ+BCNU, BG+BCNU and
BG+STZ+BCNU are reproduced for comparison.

The

combination of BG+BCNU produced significantly greater
anti-tumor activity on days 9, 12, 17, and 20 (p < 0.03)
than STZ+BCNU.

Similarly, the combination of BG+STZ+BCNU

produced greater anti-tumor activity than STZ+BCNU on
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Table 5.4:
Toxicities of STZ, BCNU, or the combinations of BG+STZ,
BG+BCNU, STZ+BCNU, BG+STZ+BCNU
Female nude micea bearing SF767 xenograf ts were
sequentially administered BG, STZ, and/or BCNU i.p. at 1
hr intervals. Animal weights were measured twice weekly
for 23 days.

Combination
(mg/kg)

STZ ( 100)
BCNU (15)
BG ( 8 0) + STZ ( 100)
BG ( 8 0) + BCNU (15)
STZ ( 100) + BCNU ( 15)
BG (15) + STZ ( 100)
+ BCNU (15)

a
b

Mean maximum
weight loss (%)

<1
<1
<1
4.8
<1

# of animal
deathsb

%
%
%
%
%

0/7
0/6
0/7
0/8
0/7

2.4 %

0/7

NIH Swiss nude mice
Number of animal deaths/number of animals treated
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days 9 and 12 (p < 0.05).

However, the three drug

combination of BG+STZ+BCNU provided no greater anti-tumor
activity than BG+BCNU.

Additionally, the administration

of all combinations of BG, STZ, and BCNU did not
appreciably increase nude mouse toxicities (Table 5.4).
These data demonstrate the feasibility using the
combination of BG and STZ to provide extended depletion
of MGMT for 24 hr without exacerbating BCNU toxicities.
However, the potential therapeutic benefit offered by the
addition of STZ to the BG+BCNU combination could not be
demonstrated in the nude mouse subcutaneous anti-tumor
model.

The doses of STZ in this model were probably

limited by mouse toxicities due to low levels of MGMT
activity in host tissues.

Consistent with this

interpretation was that a single dose of 100 mg/kg STZ
which was ineffective in depleting xenograft MGMT,
nevertheless, produced complete ablation of renal and
hepatic MGMT activity (Figure 5.5).

These data

demonstrate that in the nude mouse subcutaneous antitumor model, BG as a single agent can produce complete
depletion of MGMT for 12 hr, greater anti-tumor activity
than STZ+BCNU, and anti-tumor activity equivalent to the
three-drug combination.
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Figure 5.5:
The effect of STZ on MGMT activity in SF767 xenografts,
kidneys, and livers of NIH swiss nude mice.
Animals were injected i.p. with normal saline or STZ at
the dose of 100 mg/kg, 200 mg/kg, and 300 mg/kg. Animals
were sacrificed six hours following drug treatment
animals were sacrificed. The bracketed doublet lanes
represent MGMT activity with in a single tumor or organ
where the 0 6 -methylguanine containing probe was incubated
with 10 or 25 µg protein.
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Discussion

The primary goal of the experiments described in this
chapter was to evaluate the effectiveness of the combined
use of two MGMT depleting agents, BG and STZ, in
reversing BCNU resistance in in vivo.

The effects of the

combination of BG+STZ on the repletion of MGMT and the
enhancement of BCNU cytotoxicity was initially measured
in cultured SF767 cells.

The sequential administration

of BG and STZ sensitized SF767 cells to BCNU cytotoxicity
and produced a more prolonged inhibition of MGMT activity
than either agent alone.

The combined use of BG+STZ

depleted MGMT activity for 24 hr and produced
approximately 2 logs of synergistic BCNU cell kill.
Consistent with these in vitro observations, the
combination of BG+STZ also produced a more prolonged
inhibition of MGMT activity in SF767 xenografts than
either agent alone.

The combination produced sustained

inactivation of MGMT activity for 24 hr in the
xenografts.

Both combinations, BG+BCNU and BG+STZ+BCNU,

produced significant inhibition of tumor growth for 9 to
23 days after treatment and demonstrated a greater antitumor activity than STZ+BCNU.
The use of STZ as a BCNU resistance modulator in vivo
appears to be limited.

STZ at 100 mg/kg administered

i.p. did not deplete MGMT activity in SF767 xenografts
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but completely depleted renal and hepatic MGMT activity
(Figure 5.5).

Furthermore, a 300 mg/kg dose of STZ

produced only a 35% reduction in xenograft MGMT (Figure
5.5).

Because this particular dose of STZ was close to

the acute LD50 dose (360 mg/kg)

(Iwasaki et al., 1976),

the concentrations required to inhibit neoplastic MGMT
activity would be expected to produce unacceptable host
toxicity and thereby provide no beneficial change in the
therapeutic index of BCNU.

Similarly, Friedman et al.

(1992) administered 300 mg/kg of STZ to BALB/c mice
bearing medulloblastoma and glioblastoma tumors and found
that this dose of STZ did not appreciably deplete MGMT
activity, nor did it enhance BCNU sensitivity.

Moreover,

the DNA methylating agents temozolamide and dacarbazine
were also ineffective in sensitizing SF767 xenografts to
BCNU cytotoxicity (Mitchell and Dolan, 1993).

These data

suggest that methylating agents should not be used as
single agents for CENU resistance modulation.

However,

STZ might be useful when added to the BG+BCNU regimen.
It may be advantageous to use a MGMT depleting agent with
intrinsic anti-tumor activity, such as STZ, in
combination with BG.

In the sequential administration of

BG, STZ, and BCNU, BG can deplete MGMT, and thereby allow
a greater number of STZ induced 0 6 -methylguanine lesions
to persist and deplete MGMT for extended periods.

These

additional STZ lesions could act in concert with BCNU
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adducts to increase the tumor cell lesion burden and
produce a greater clinical anti-tumor activity.

This

rationale for the use of the three-drug combination was
detailed in chapter 4.

The 0 6 -methylguanine lesion has

been considered to be more mutagenic than cytotoxic.
However, recent observations by Kaina et al.

(1991)

demonstrated that transf ection of MGMT and ada
complementary DNAs into MGMT deficient cells produced
significant protection against methylating agent
cytotoxicity, as well as mutagenesis.

This cytotoxic

potential of STZ induced 0 6 -methylguanine lesions could be
maximized when combined with BG.
The combination of BG+STZ+BCNU produced extended
depletion of MGMT and greater cytotoxicity than BG+BCNU
or STZ+BCNU in both HT-29 and SF767 cell lines.

The pre-

treatment regimens which provided sustained inhibition of
MGMT for at least 24 hr after BCNU treatment produced the
greatest potentiation of BCNU cytotoxicity in vitro.

The

enhancement of BCNU cytotoxicity in SF767 cells was
markedly less than in HT-29 cells.

This lower

enhancement in SF767 cell line would be expected because
the magnitude of enhancement of CENU cytotoxicity is a
function of cellular MGMT content (Dolan., 1991; Chen et
al., 1993a,b), and because SF767 cells contains a 30 %
lower MGMT activity than HT-29 cells.
At the maximally tolerated doses, the combination of
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BG+STZ+BCNU produced significant inhibition of tumor
growth.

However, this three-drug combination provided no

greater anti-tumor activity than BG+BCNU.

Both regimens

produced significant inhibition of tumor growth for 9-23
days and produced minimal host toxicity.

These data

suggest that the addition of STZ to a BG+BCNU regimen
might not be necessary.

In the mouse, ample tumor

concentrations of BG were reached to inactivate MGMT for
12 hr and this prolonged inhibition appeared to be
sufficient in maximizing tumor responses in the xenograft
model.

These and other data strongly recommend the

clinical testing of the combination of BG+BCNU (Dolan et
al., 1990a,b; 1991; Mitchell et al., 1992; Gerson et al.,
1993; Friedman et al., 1992).

However, one may not

achieve high enough plasma concentrations of BG to
inactivate tumors with high levels of MGMT for a
prolonged period due to the limited solubility of the
compound.

This difficulty could be resolved by the

repeatedly administering of BG following BCNU
administration, or by using the combination of BG+STZ.
Repeated administration of BG provides complete depletion
of MGMT activity 24 hr and potentiates BCNU cytotoxicity
in cultured cells and tumor xenografts (Gerson et al.,
1993).

Alternatively, the combined use of BG and STZ

could not only provide extended depletion of MGMT, but
also the addition of STZ-induced DNA damage could
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potentially contribute to clinical anti-tumor activity.
The advantages and disadvantages of the combined use of
BG and STZ in BCNU resistance modulation is further
discussed below.
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CHAPTER VI
SUMMARY

The experiments described within this dissertation
tested whether extended depletion of MGMT activity
following BG, dBG, and/or STZ was required for maximal
enhancement of BCNU cytotoxicity in CENU resistant cell
lines.

The potentiation of BCNU cytotoxicity was

examined after complete inhibition, partial or complete
recovery of MGMT activity 24 hr following BG, dBG, and
STZ treatment.
The pretreatment regimens which provided the greatest
potentiation of BCNU cytotoxicity were those exhibiting
the most prolonged depletion of MGMT activity.

Treatment

of HT-29 cells with a 10 µM dose of BG resulted in
complete inactivation of MGMT immediately after drug
treatment, with a recovery of approximately 15% of
control activity in 3-24 hr.

This partial recovery of

MGMT activity was completely inhibited for 24 hr by
combining BG (10 µM) with STZ (1.0 mM), or by increasing
the dose of BG to 100 µM.

The prolonged depletion of

MGMT activity provided by the combination of BG (10 µM)

+

STZ (1.0 mM) or BG (100 µM) was associated with a greater
enhancement of BCNU cytotoxicity than the dose of lOµM
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BG.

Additionally, the recovery rate of MGMT activity

following BG (100 µM) or dBG (1.0

mM)

treatment was

modulated by repeated washing of cells with complete
medium.

Subsequent to BG (100 µM) or dBG (1.0

mM)

treatment, MGMT activity was completely inactivated for
24 hr.

Additionally, this pretreatment regimen enhanced

BCNU cytotoxicity by 3 logs.

MGMT activity recovered to

control levels by 24 hr, and BCNU cell kill was
coordinately reduced to less than one log when cells were
pretreated with BG or dBG and washed four times with
serum containing medium.

When this recovery was

completely inhibited for 24 hr by combining BG or dBG
with a 2.5 mM dose of STZ, BCNU cytotoxicity was
potentiated by 4 logs.

These data indicate that MGMT

should be depleted prior to, and for an extended period
following BCNU treatment.

The extended depletion of MGMT

may allow an increased number of BCNU interstrand crosslinks resulting in greater cytotoxicity. Furthermore, the
sequential administration of the direct MGMT depleting
agents BG or dBG, and STZ probably results in a greater
number of STZ-induced 0 6 -methylguanine lesions which are
responsible for the extended depletion of MGMT.

The

consistently greater enhancement of BCNU cytotoxicity by
the combination of BG+STZ or dBG+STZ than by BG alone
under conditions of comparable MGMT depletion, suggests
that the greater number of STZ lesions act in concert
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with BCNU alkylation to produce the greater cytotoxicity
in vitro.
This rationale for the combined use of BG and STZ in
BCNU resistance modulation was tested in vivo utilizing
the SF767 subcutaneous xenograft anti-tumor model.
Consistent with the in vitro observations, the
combination of BG+STZ produced near complete depletion of
MGMT for 24 hr, whereas BG alone allowed a recovery of
40% control MGMT activity by 24 hr.

The sequential

administration of BG, STZ, and BCNU, at maximally
tolerated doses produced no greater anti-tumor activity
than the combination of BG+BCNU in vivo.
Collectively, these data suggest that clinical
chemotherapeutic regimens targeting the inactivation of
MGMT, and the reversal of BCNU resistance, should be
optimized such that MGMT is depleted prior to, and for an
extended period after BCNU treatment.

If extended

depletion of MGMT cannot be achieved with BG due to
solubility limitations in a clinical setting, then this
difficulty may be overcome in two ways: i) repeated
administrations of BG could provide complete depletion
for 24 hr and potentiate BCNU cytotoxicity in vitro and
in vivo (Gerson et al., 1993); ii) alternatively, BG
could be combined with STZ.

The latter regimen could act

as a proverbial double-edged sword.

Serial

administration of BG and STZ could not only provide
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extended depletion of MGMT, but also the enhanced number
of 0 6 -methylguanine lesions could contribute to anti-tumor
activity.
If clinical CENU resistance modulation were to require
multiple cycles of chemotherapy, the combined use of BG
and STZ could also prevent the possible selection of BG
resistant tumor cells.

A single point mutation within

MGMT has been demonstrated to impair the MGMT-mediated
repair of BG, whereas the repair of 0 6 -methylguanine in
DNA was unaffected (Crone and Pegg, 1993).

The addition

of STZ to a BG+BCNU regimen could provide ample levels of
0 6 - methylguanine in DNA which could inactivate BG
resistant MGMT, and thereby facilitate BCNU cell killing.
A potential clinical disadvantage to the BG+STZ+BCNU
regimen could be an increased risk of secondary
malignancies.

MGMT plays a pivotal role in the

prevention of methylating agent induced mutagenesis and
carcinogenesis (Kaina et al., 1991; Dumenco et al.,
1993).

Presentation of methylating agent-induced pro-

carcinogenic lesions when MGMT is depleted with BG could
conceivably increase mutation rate, and thereby increase
the possibility of secondary neoplastic transformation.
The combination of BG+BCNU has produced promising
results in pre-clinical studies.

The clinical testing of

this regimen should consider the importance of extended
depletion of MGMT in maximizing CENU cytotoxicity.

With
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the development of treatment modalities which can
selectively deliver BG to tumor cells, an increased CENU
therapeutic index and spectrum of clinical activity is
anticipated.
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APPENDIX I

Upon review of the literature concerning the
modulation of alkylating agent resistance, Tiecher and
Frei (1991) concluded that neoplastic drug resistance is
multifactorial and optimal clinical modulation of such
resistance should target multiple resistance mechanisms
simultaneously.

Utilizing this rationale, the effect of

combined depletion of MGMT and GSH on BCNU sensitivity in
HT-29 cells was examined (Figure A.1).

Cells were

sequentially administered BSO, BG, and BCNU.

Partial and

complete depletion of GSH and MGMT, respectively,
resulted in a greater enhancement of BCNU cytotoxicity
than any two-drug regimen.

BG increased BCNU (100 µM)

cell killing by approximately 1.5 logs, and the addition
of BSO to this regimen provided an additional 0.5 log of
cytotoxicity.

These data suggest that GSH may indeed be

a secondary mechanism of CENU resistance in CENU
resistant cells and further development of regimens
targeting multiple mechanisms of resistance may be
warranted.
Pretreatment of brain tumor cell lines with
diflouromethylornithine (DFMO), an inhibitor of the rate
limiting enzyme in polyamine synthesis, decreased
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Figure A.l:
The effects of sequential administration of BSO, BG, and
BCNU on HT-29 cytotoxicity

Cells were treated with BSO (25 µM) and BG (10 µM) for 24
hr and 2 hr, respectively, prior to a 1 hr exposure to
BCNU. BSO at a dose of 25 µM produced approximately 80%
reduction in GSH content in HT-29 cells after 24 hr of
exposure (Hantel et al., 1991). The 10 µM dose of BG
utilized represents the IC 100 dose for MGMT inhibition
(Chapter 3). The combination of BSO+BG was non-cytotoxic
(data not shown) . The tissue culture and survival assay
protocols were described in the material and methods
section of chapter 3. The points represent the mean +/SD of survival values in 3 or more replicate flasks in a
single experiment.
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spermidine and putrescine levels, and increased BCNU
cytotoxicity (Hunget al., 1981; Seidenfeld and Komar,
1985).

The decrease in polyamine levels appears to be

related to an increased DNA damaging effects of BCNU.
The combined depletion of MGMT and ornithine
decarboxylase by BG and difluromethylornithine produces
greater cytotoxicity than BG+BCNU or DFMO+BCNU (M.E.
Dolan, personal communication) .

Furthermore, the

topoisomerase II inhibitor novobiocin markedly increases
the antitumor effect of BCNU (Ross, 1985; Eder et al.,
1989) . This inhibition may prevent the disaggregation of
chromosomes in the G2 and M periods of the cell cycle and
concurrently inhibit DNA repair.

Therefore, it could be

of therapeutic interest to simultaneously deplete MGMT,
polyamine levels and inhibit topoisomerase II.
Modulation of multiple mechanisms of CENU resistance
could coordinately allow a greater DNA damage and a lower
DNA repair proficiency.

The increased DNA damage or

impairment of DNA repair would be expected to increase
the clinical antitumor activity of BCNU than depletion of
MGMT alone.
Therefore, a multimodulatory approach could also
decrease the possibility of acquired cellular resistance
to BG.

A single point mutation within the MGMT cDNA

markedly decreases BG sensitivity, and therefore mediate
BG resistance (Crone and Pegg, 1993).

Repeated
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administration of BG+BCNU could result in the selection
of a subpopulation of tumor cells expressing BG resistant
MGMT.

Concurrent targeting of multiple sites of CENU

resistance could result in a greater cell killing and
possibly prevent the re-establishment of tumor mass by
BG-resistant cells.
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Appendix II
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Figure A.2:
The effect of increasing amounts of MGMT containing
extract incubated with approximately 0.2 pmoles of 0 6 methylguanine containing DNA on the percentage of probe
cleaved.
The radiolabelled probe was incubated with 0-100 µg of
HT-29 whole cell sonicate for 2 hr at 37°C.
The protocol
used in this experiment was described in the "Methods and
Materials" section of chapter 3.
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